Rich Pharmaceuticals (RCHA) S-1 14 Apr 17 2016 FY IPO registration Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2016	Jul. 03, 2016	Sep. 30, 2015
Document And Entity Information
Entity Registrant Name	Rich Pharmaceuticals, Inc.
Entity Central Index Key	1,504,389
Document Type	S1
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 64,900
Entity Common Stock, Shares Outstanding		447,369,610
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Current Assets
Cash and equivalents			$ 15,892
Prepaid expenses		2,800	7,578
Total Current Assets		2,800	23,470
Property and equipment, net	2,437	3,731	788
TOTAL ASSETS	2,437	6,531	24,258
Current Liabilities
Bank overdraft	405	2,948
Accounts payable	366,564	1,139,431	910,272
Accrued expenses	896,614	530,150	200,891
Due to related parties	49,593	76,913	6,067
Note payable	900,000
Convertible notes payable, net of debt discount	376,302	201,879	402,131
Derivative liabilities	618,060	446,912	139,983
Total Current Liabilities	3,207,538	2,398,233	1,659,344
Long-term Liabilities
Convertible notes payable, net of debt discount			6,080
Derivative liabilities			77,775
Total Long-term Liabilities			83,855
Total Liabilities	3,207,538	2,398,233	1,743,199
Stockholders Deficit
Preferred stock, $.001 par value, 10,000,000 shares authorized, 6,000,000 shares issued and outstanding, respectively	6,000	6,000	6,000
Common stock, $0.001 par value, 4,000,000,000 shares authorized, 216,364,262 and 15,410,840 shares issued and outstanding,	1,307,401	216,364	15,411
Additional paid-in capital	5,670,271	6,589,374	5,694,628
Accumulated deficit	(10,188,773)	(9,203,440)	(7,434,980)
Total Stockholders Deficit	(3,205,101)	(2,391,702)	(1,718,941)
TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT	$ 2,437	$ 6,531	$ 24,258

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	May 23, 2016	Mar. 31, 2016	Mar. 31, 2015	Sep. 06, 2013	Sep. 05, 2013
Statement of Financial Position [Abstract]
Common Stock, Par Value	$ 0.001		$ 0.001	$ .001	$ 0.001	$ 0.001
Common Stock, Shares Authorized	4,000,000,000	4,000,000,000	4,000,000,000	4,000,000,000	375,030,000	900,000
Common Stock, Issued	1,307,401,310		216,364,262	15,410,840
Preferred Stock, Par Value	$ 0.001		$ .001	$ .001
Preferred Stock, Shares Authorized	10,000,000		10,000,000	10,000,000
Preferred Stock, Issued	6,000,000		6,000,000	6,000,000

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Consulting expenses	10,325	4,300	26,400	10,300	16,000	200,925
Office expenses	24,612	30,361	94,658	76,255	110,600	97,821
Depreciation expense	431	206	1,293	443	799	473
Wages and taxes	95,955	100,326	287,911	283,119	383,937	727,458
Professional fees	57,525	105,339	145,926	197,623	267,778	1,339,623
Regulatory fees	(1,664)	1,510	7,865	18,759	29,356	52,496
Research and development				9,000	16,823	165,371
Stock-based compensation				198,128	240,999	866,128
Impairment of intangible asset						82,120
Travel, meals and entertainment	21,632	21,205	43,035	35,797	51,313	74,010
TOTAL OPERATING EXPENSES	208,816	298,595	607,088	859,036	1,117,605	3,606,425
LOSS FROM OPERATIONS	(208,816)	(298,595)	(607,088)	(859,036)	(1,117,605)	(3,606,425)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(33,006)	(134,975)	(105,366)	(405,963)	(531,638)	(504,269)
Change in value of derivative liability	(84,508)	(399,810)	83,946	(169,624)	563,432	1,867,621
Derivative expense	(170,250)	(47,469)	(170,250)	(382,713)	497,213	1,809,914
Forgiveness of debt						6,009
Interest expense	(43,715)	(19,872)	(186,189)	(40,127)	(185,136)	(56,531)
Interest expense related party	(155)	(2)	(385)	(226)	$ (300)	$ (67)
Loss on share issuance						$ (30,000)
Other Income Total	(331,634)	(602,128)	(378,244)	(998,653)	$ (650,855)	$ (527,151)
LOSS BEFORE PROVISION FOR INCOME TAXES	(540,450)	(900,723)	(985,332)	(1,857,689)	(1,768,460)	(4,133,576)
PROVISION FOR INCOME TAXES
NET LOSS	$ (540,450)	$ (900,723)	$ (985,332)	$ (1,857,689)	$ (1,768,460)	$ (4,133,576)	$ (3,004,937)
NET LOSS PER SHARE: BASIC AND DILUTED	$ 0	$ (0.02)	$ 0	$ (0.03)	$ (0.02)	$ (0.65)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	838,312,685	46,854,700	611,216,176	63,288,358	76,021,284	6,331,803

Condensed Statements of Operati

Condensed Statements of Operations 9M - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Consulting expenses	10,325	4,300	26,400	10,300
Office expenses	24,612	30,361	94,658	76,255
Depreciation expense	431	206	1,293	443
Wages and taxes	95,955	100,326	287,911	283,119
Professional fees	57,525	105,339	145,926	197,623
Regulatory fees	(1,664)	1,510	7,865	18,759
Research and development				9,000
Stock-based compensation		35,348		227,740
Travel, meals and entertainment	21,632	21,205	43,035	35,797
TOTAL OPERATING EXPENSES	208,816	298,595	607,088	859,036
LOSS FROM OPERATIONS	(208,816)	(298,595)	(607,088)	(859,036)
OTHER INCOME (EXPENSE)
Amortization of debt discount	(33,006)	(134,975)	(105,366)	(405,963)
Change in value of derivative liability	(84,508)	(399,810)	83,946	(169,624)
Derivative expense	(170,250)	(47,469)	(170,250)	(382,713)
Interest expense	(43,715)	(19,872)	(186,189)	(40,127)
Interest expense related party	(155)	(2)	(385)	(226)
Other Income Total	(331,634)	(602,128)	(378,244)	(998,653)
LOSS BEFORE PROVISION FOR INCOME TAXES	(540,450)	(900,723)	(985,332)	(1,857,689)
PROVISION FOR INCOME TAXES
NET LOSS	$ (540,450)	$ (900,723)	$ (985,332)	$ (1,857,689)
NET LOSS PER SHARE: BASIC AND DILUTED	$ 0	$ (0.02)	$ 0	$ (0.03)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	838,312,685	46,854,700	611,216,176	63,288,358

Shareholders Equity

Shareholders Equity - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning balance, shares at Mar. 31, 2014	6,000,000	4,144,114
Beginning balance, amount at Mar. 31, 2014	$ 6,000	$ 4,144	$ 2,453,957	$ (3,301,404)	$ (837,303)
Issuance of common stock for cash, shares		799,619
Issuance of common stock for cash, amount		$ 800	219,200		220,000
Stock issued for intangible assets, shares		2,207,920
Stock issued for intangible assets, amount		$ 2,208	7,902,147		7,940,355
Deemed dividend for intangibles			(7,822,235)		(7,822,235)
Stock options granted for services			815,680		815,680
Stock and warrants issued for cash, shares		24,833
Stock and warrants issued for cash, amount		$ 25	339,975		340,000
Stock issued for services, shares		16,000
Stock issued for services, amount		$ 160	795,890		796,050
Stock issued for stock deposits, shares		14,690
Stock issued for stock deposits, amount		$ 15	147,035		147,050
Stock issued for debt conversion, shares		8,059,664
Stock issued for debt conversion, amount		$ 8,059	491,627		499,686
Derivative liability closed to APIC			300,904		300,904
Stock option modification			50,448		50,448
Net loss				(4,133,576)	(4,133,576)
Ending balance, shares at Mar. 31, 2015	6,000,000	15,410,840
Ending balance, amount at Mar. 31, 2015	$ 6,000	$ 15,411	$ 5,694,928	$ (7,434,980)	$ (1,718,941)
Stock and warrants issued for cash, shares			42,871		42,871
Stock issued for services, shares		6,350,381
Stock issued for services, amount		$ 6,350	$ 42,805		$ 49,155
Stock issued for debt conversion, shares		194,603,041
Stock issued for debt conversion, amount		$ 194,603	407,771		602,374
Derivative liability closed to APIC			203,171		203,171
Stock option modification			56,779		56,779
Net loss				(1,768,460)	(1,768,460)
Ending balance, shares at Mar. 31, 2016	6,000,000	216,364,262
Ending balance, amount at Mar. 31, 2016	$ 6,000	$ 216,364	$ 6,589,374	$ (9,203,440)	(2,391,702)
Net loss					(985,332)
Ending balance, amount at Dec. 31, 2016					$ (3,205,101)

Shareholders Equity (Parentheti

Shareholders Equity (Parenthetical)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Sep. 30, 2013	Mar. 31, 2013
Statement of Stockholders' Equity [Abstract]
Forward Split	0.01	4.167	4.167	4.1671

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (1,768,460)	$ (4,133,576)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	799	473
Amortization of debt discount	531,638	504,269
Change in value of derivative liability	(563,432)	(1,867,621)
Derivative expense	497,213	1,809,914
Forgiveness of debt		$ (6,009)
Loss on share issuance		$ 30,000
Impairment of intangible asset		$ 82,120
Stock issued for services	49,155	796,050
Stock-based compensation	240,999	866,128
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses	4,778	(6,017)
Increase in bank overdraft	2,948
Increase in accounts payable	229,159	729,600
Increase (decrease) in accrued expenses	329,259	(250,399)
Net Cash Used by Operating Activities	(495,099)	(1,445,068)
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of assets	(3,741)
Net Cash Used by Investing Activities	(3,741)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans and interest received (repaid)		(29,933)
Loans received (repaid) from/to related parties	70,846
Proceeds from sale of common stock and warrants	49,156	560,000
Proceeds from issuance of convertible notes payable	362,947	918,506
Net Cash Provided by Financing Activities	482,948	1,448,573
Net Increase (Decrease) in Cash and Cash Equivalents	(15,892)	3,505
Cash and cash equivalents, beginning of period	15,892	12,387
Cash and cash equivalents, end of period		15,892
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Stock deposits reclassified as common stock and stock warrants		147,050
Original issue discounts recorded on notes payable	12,900	612,827
Debt discounts recorded on convertible notes payable	498,544
Acquisition of intangibles for stock		82,120
Debt/interest converted into common stock	$ 602,374	$ 499,686

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows 9M - USD ($)	9 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (985,332)	$ (1,857,689)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	1,293	443
Amortization of debt discount	105,366	405,963
Change in value of derivative liability	(83,946)	169,624
Derivative expense	(170,250)	(382,713)
Interest converted into stock	9,584
Warrants issued for services		42,871
Stock-based compensation		198,128
Changes in operating assets and liabilities:
Decrease in prepaid expenses	2,800	7,578
Increase (decrease) in bank overdraft	(2,543)
Increase (decrease) in accounts payable	127,133	70,247
Increase in accrued expenses	366,464	237,110
Net Cash Used by Operating Activities	(288,931)	(343,012)
CASH FLOWS FROM INVESTING ACTIVITY:
Acquisition of assets		(1,054)
Net Cash Used by Investing Activities		(1,054)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loans received (repaid) from/to related parties	(27,319)	64,011
Proceeds from sale of common stock and warrants		62,415
Proceeds from issuance of convertible notes payable	316,250	205,171
Net Cash Provided by Financing Activities	288,931	331,597
Net Increase (Decrease) in Cash and Cash Equivalents		(12,469)
Cash and cash equivalents, beginning of period		15,892
Cash and cash equivalents, end of period		3,423
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING INFORMATION:
Stock deposits reclassified as common stock/warrants
Accounts payable converted into note payable	900,000
Common stock issued for accrued expenses
Original issue discounts recorded on notes payable		10,400
Debt discounts recorded on convertible notes payable	147,632	396,402
Acquisition of intangibles for stock
Debt/interest converted into common stock and contributed capital	$ 109,144	$ 454,077

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At December 31, 2016 and March 31, 2016 the Company had $- and $-, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at December 31, 2016 or March 31, 2016. As of December 31, 2016, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.	Nature of Business On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2016 and 2015 the Company had $0 and $15,892, respectively, of unrestricted cash. Basis of Presentation The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015, as filed with the U.S. Securities and Exchange Commission. Property and Equipment Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years. Long-Lived and Intangible Assets The Company accounts for long-lived and intangible assets in accordance with ASC Topic 360-10-05, “Accounting for the Impairment or Disposal of Long-Lived Assets.” ASC Topic 360-10-05 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value or disposable value. As of March 31, 2014, the Company fully impaired their intangible assets to $0. During the year ended March 31, 2015, the Company acquired another intangible asset from a related party and valued it at the cost of the intangible to the related party totaling $82,120. As of March 31, 2015, the Company fully impaired their intangible assets to $0. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Fair Value of Financial Instruments (continued) Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at March 31, 2016 or 2015. As of March 31, 2016, the derivative liabilities were considered a level 2 item; see Note 8. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Revenue Recognition The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. Research and Development The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes. Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share. Basic Loss Per Share The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. Recent Accounting Pronouncements The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment

Property and equipment	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property and equipment	Property and equipment, recorded at cost, consisted of the following as of December 31, 2016 and March 31, 2016: December 31, 2016 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (2,723 ) (1,429 ) Property and equipment, net $ 2,437 $ 3,731 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $1,293 and $799 for the periods ended December 31, 2016 and March 31, 2016, respectively.	Property and equipment, recorded at cost, consisted of the following as of March 31, 2016 and 2015: March 31, 2016 March 31, 2015 Computer equipment & furniture $ 5,160 $ 1,419 Less: accumulated depreciation (1,429 ) (631 ) Property and equipment, net $ 3,731 $ 788 The useful life of the computer equipment and furniture is 3 years. Depreciation expense was $799 and $473 for the years ended March 31, 2016 and 2015, respectively .

Intangible Assets

Intangible Assets	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.

Accrued Expenses

Accrued Expenses	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consisted of the following as of December 31, 2016 and March 31, 2016: December 31, 2016 March 31, 2016 Wages and taxes $ 799,711 $ 514,713 Accrued interest 96,903 15,437 Total accrued expenses $ 896,614 $ 530,150	Accrued expenses consisted of the following as of March 31, 2016 and 2015: March 31, 2016 March 31, 2015 Wages and taxes $ 514,713 $ 175,357 Accrued interest 15,437 25,534 Total accrued expenses $ 530,150 $ 200,891

Related Party Debt and Transact

Related Party Debt and Transactions	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Debt and Transactions	On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015. Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. During the period ended December 31, 2016 the Company received an additional $6,280 from this related party. The loan is unsecured and bears 8% interest. There is a total due of $12,280 as of December 31, 2016. Interest accrued on the note as of December 31, 2016 was $597. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $28,200 in unsecured non-interest bearing loans from related parties and during the period ending December 31, 2016 received an additional $20,730, and has repaid $36,300 of these loans leaving a total due of $12,630 as of December 31, 2016. These loans are deemed to be short-term and are payable at the discretion of the Company. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 30,002 shares of common stock at an exercise price of $2.00 per share. The CEO earned $206,250 and $275,000 for the periods ended December 31, 2016 and March 31, 2016 (respectively) as a result of this agreement, these amounts contribute to the $600,112 and $395,630 of officer compensation which is included in accrued expenses, as of December 31, 2016 and March 31, 2016.	On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with its boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. During the year ended March 31, 2015 and 2014, the Company received loans from companies controlled by its new CEO or shareholders totaling $5,000 and $36,000, respectively. The loans are unsecured, non-interest bearing with no specific terms of repayment. The Company repaid all $41,000 of the loans during the year ended March 31, 2015. Also during the year ended March 31, 2015, the Company received a $6,000 loan from a shareholder. The loan is unsecured and bears 8% interest. There is a total due of $6,000 as of March 31, 2016. Interest accrued on the 2015 note as of March 31, 2016 was $367. The Company is in default on the balance of this note. During the period ending March 31, 2016, the Company received $46,900 in unsecured non-interest bearing loans from related parties, and has repaid $24,700 of these loans leaving a total due of $22,200 as of March 31, 2016. These loans are deemed to be short-term and are payable at the discretion of the Company. On September 6, 2013, the Company entered into an Employment Agreement with our Chief Executive Officer, Chief Financial Officer, President and Secretary. The Employment Agreement provides for a term of two years; annual compensation of $275,000, a signing bonus of $68,750, and options to purchase up to 30,002 shares of common stock at an exercise price of $2.00 per share. The CEO earned $275,000 and $275,000 for the years ended March 31, 2016 and 2015 (respectively) as a result of this agreement, these amounts contribute to the $395,630 and $154,062 of officer compensation which is included in accrued expenses, as of March 31, 2016 and 2015.

Stock Deposits

Stock Deposits	12 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
Stock Deposits	The Company received deposits for future stock purchases during the year ended March 31, 2014 totaling $147,050. The Company signed subscription agreements with four investors on June 16, 2014 to grant 14,690 shares of common stock in exchange for the deposits. The remaining balance as of March 31, 2015 and 2016 is $0.

Note Payable 9M

Note Payable 9M	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Debt Disclosure [Abstract]
Note Payable	On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 177,836 shares of common stock leaving a remaining balance of accrued interest of $0 as of March 31, 2016. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016 . On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of December 31, 2016 is $11,819. The Company is in default on the balance of this note. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 46,484,586 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock. During the period ending December 31, 2016 the note holder converted $60,439 in principal and $6,839 in accrued interest into 891,020,080 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of . On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of . The Company is in default on the balance of this note. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending , 2016 the note holder converted $15,000 in principal and $939 in accrued interest into 87,032,383 shares of common stock leaving a remaining balance of $0. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of is $19,000, and On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016 , The loan becomes convertible on , 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. The Company is in default on the balance of this note. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of is $5,702. The Company is in default on the balance of this note. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date.. During the period ending the note holder converted $16,745 in principal and $1,380 in interest into 66,500,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. . On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of December 31, 2016 is $3,804. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of December 31, 2016 is $2,344. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017,	On March 11, 2014, the Company issued a convertible promissory note in the amount of $37,500. The note is due on December 13, 2014 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $37,500 of principal and $1,500 of interest into 21,593 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On April 8, 2014, the Company issued a convertible note payable in the amount of $53,000. The note bears 8% interest and is due on January 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date . On May 21, 2014, the Company issued a convertible note payable in the amount of $42,500. The note bears 8% interest and is due on February 23, 2015. The note is currently in default. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $42,500 of principal and $1,700 of interest into 152,524 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $3,380. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $66,780 of principal and $2,850 of interest into 1,214,425 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $58,300 of principal and $2,527 of interest into 1,310,912 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 177,836 shares of common stock leaving a remaining balance of accrued interest of $0. On August 19, 2014, the Company issued a convertible note payable in the amount of $57,895 including an original issue discount of $2,895. The note bears 12% interest and is due on August 19, 2016. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $57,895 of principal and $14,035 of interest (including a $10,000 penalty) into 1,798,250 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March31, 2016. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of March 31, 2016 is $4,738. The Company is in default on the balance of this note. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on December 9, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock leaving a remaining balance of $16,215. The Company is in default on the balance of this note. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock leaving a remaining balance of $60,439. Accrued interest was $4,387 as of March 31, 2016. On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of March 31, 2016. The Company is in default on the balance of this note. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of March 31, 2016 is $15,000, and i On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of March 31, 2016 is $19,000, and On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and is due on December 30, 2016. The loan becomes convertible on , 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of March 31, 2016 is $1,144. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $5,315 in principal into 11,682,000 shares of common stock leaving a remaining balance of $27,500. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. .

Convertible Note Payable

Convertible Note Payable	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible Note Payable	On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 177,836 shares of common stock leaving a remaining balance of accrued interest of $0 as of March 31, 2016. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016 . On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of December 31, 2016 is $11,819. The Company is in default on the balance of this note. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and was originally due on December 9, 2015, with a revised due date of June 23, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock. During the period ending June 30, 2016 the note holder converted $7,377 in principal and $422 in accrued interest into 46,484,586 shares of common stock leaving a remaining balance of $ 8,838. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) days prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock. During the period ending December 31, 2016 the note holder converted $60,439 in principal and $6,839 in accrued interest into 891,020,080 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of . On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of . The Company is in default on the balance of this note. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending , 2016 the note holder converted $15,000 in principal and $939 in accrued interest into 87,032,383 shares of common stock leaving a remaining balance of $0. On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of is $19,000, and On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and was originally due on December 30, 2016 , The loan becomes convertible on , 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. The Company is in default on the balance of this note. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of is $5,702. The Company is in default on the balance of this note. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date.. During the period ending the note holder converted $16,745 in principal and $1,380 in interest into 66,500,000 shares of common stock leaving a remaining balance of $10,755. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. . On June 8, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250. The note bears interest at the rate of 8% and must be repaid on or June 8, 2017. The note and any accrued interest may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of December 31, 2016 is $3,804. On June 23, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion. Interest accrued as of December 31, 2016 is $2,344. On July 7, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $58,000. The note bears interest at the rate of 8% and must be repaid on or July 7, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On October 20, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $32,000. The note bears interest at the rate of 8% and must be repaid on or October 20, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017, On November 17, 2016, the Company issued an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000. The note bears interest at the rate of 8% and must be repaid on or June 23, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, 180 days after issuance or January 3, 2017,	On March 11, 2014, the Company issued a convertible promissory note in the amount of $37,500. The note is due on December 13, 2014 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $37,500 of principal and $1,500 of interest into 21,593 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On April 8, 2014, the Company issued a convertible note payable in the amount of $53,000. The note bears 8% interest and is due on January 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date . On May 21, 2014, the Company issued a convertible note payable in the amount of $42,500. The note bears 8% interest and is due on February 23, 2015. The note is currently in default. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $42,500 of principal and $1,700 of interest into 152,524 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $3,380. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $66,780 of principal and $2,850 of interest into 1,214,425 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 14, 2014, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $58,300 of principal and $2,527 of interest into 1,310,912 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On August 13, 2014, the Company issued a convertible note payable in the amount of $61,111 including an original issue discount of $5,500. The note has a one-time 12% interest charge and is due on August 14, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $61,111 of principal and $6,266 of interest into 1,403,700 shares of common stock leaving a remaining balance of $0. During the year ended March 31, 2016, the note holder converted $1,067 of interest into 177,836 shares of common stock leaving a remaining balance of accrued interest of $0. On August 19, 2014, the Company issued a convertible note payable in the amount of $57,895 including an original issue discount of $2,895. The note bears 12% interest and is due on August 19, 2016. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $57,895 of principal and $14,035 of interest (including a $10,000 penalty) into 1,798,250 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2015. On September 18, 2014, the Company issued a convertible note payable in the amount of $64,500 including an original issue discount of $5,500. The note bears a one-time 12% interest charge and is due on September 18, 2015. The loan becomes convertible immediately upon the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. However, if the market price during the 20 day trading period (mentioned above) is below $0.03, then the conversion factor will be reduced to 55%. During the year ended March 31, 2015, the note holder converted $10,000 of principal into 181,819 shares of common stock leaving a remaining balance of $54,500. During the period ending March 31, 2016 the note holder converted $54,500 in principal and $8,240 in accrued interest into 1,879,597 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On September 23, 2014, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on June 23, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the year ended March 31, 2015, the note holder converted $25,200 of the principle into 700,000 common shares leaving a remaining balance of $29,800. During the period ending March 31, 2016 the note holder converted $29,800 in principal and $2,158 in accrued interest into 864,672 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On October 6, 2014, the Company issued a convertible promissory note in the amount of $33,000. The note is due on July 6, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,000 in principal and $1,320 in accrued interest into 780,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March31, 2016. On November 6, 2014, the Company issued a convertible promissory note in the amount of $55,000. The note is due on May 6, 2015 and bears interest at 12% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 52.5% multiplied by lowest daily market price, for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On November 25, 2014, the Company issued a convertible promissory note in the amount of $43,000. The note is due on August 28, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $3,510 to increase the balance of the note and also converted $46,510 in principal into 5,290,270 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On December 16, 2014, the Company issued a convertible note payable in the amount of $33,333 including an original issue discount of $3,333. The note bears a one-time 12% interest charge and is due on December 16, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,333 in principal and $4000 in accrued interest into 5,047,167 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On January 9, 2015, the Company issued a convertible promissory note in the amount of $33,000. The note is due on October 13, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder assessed a default fee of $16,500 to increase the balance of the note and also converted $49,500 in principal and $1,320 in interest into 8,470,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 5, 2015, the Company issued a convertible promissory note in the amount of $54,000. The note is due on November 9, 2015 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $33,020 in principal into 12,393,030 shares of common stock, and incurred a default fee of $27,000 leaving a remaining balance of $47,980. Interest accrued on this note as of March 31, 2016 is $4,738. The Company is in default on the balance of this note. On February 17, 2015, the Company issued a convertible note payable in the amount of $66,780 including an original issue discount of $6,780. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $66,780 in principal and $3,148 in accrued interest into 8,854,031 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On February 25, 2015, the Company issued a convertible note payable in the amount of $27,778 including an original issue discount of $2,778. The note bears a one-time 12% interest charge and is due on February 25, 2017. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 60% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $27,778 in principal and $3,333 in accrued interest into 5,185,210 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On March 9, 2015, the Company issued a convertible note payable in the amount of $55,000. The note bears 8% interest and is due on December 9, 2015. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $38,785 in principal and $5,135 in accrued interest into 57,733,852 shares of common stock leaving a remaining balance of $16,215. The Company is in default on the balance of this note. On March 26, 2015, the Company issued a convertible note payable in the amount of $29,680 including an original issue discount of $1,680. The note bears 8% interest and is due on March 23, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $10,929 in principal into 15,924,728 shares of common stock leaving a remaining balance of $18,751. The Company is in default on the balance of this note. On March 2, 2015, the Company issued a convertible note payable in the amount of $58,300 including an original issue discount of $3,300. The note bears 8% interest and is due on August 14, 2015. The loan becomes convertible immediately at the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twenty-two (22) trading day period ending on the latest complete trading day prior to the conversion date. On March 2, 2015 the note holder converted $56,402 of the principle into 1,215,551 common shares leaving a remaining balance of $1,898. During the period ending March 31, 2016 the note holder converted $1,898 in principal and $20 in accrued interest into 53,000 shares of common stock leaving a remaining balance of $0. Accrued interest was $0 as of March 31, 2016. On May 5, 2015, the Company issued a convertible note payable in the amount of $68,900 including an original issue discount of $3,900. The note bears 8% interest and is due on May 5, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 42% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. . During the period ending March 31, 2016 the note holder converted $8,461 in principal and $566 in accrued interest into 18,135,267 shares of common stock leaving a remaining balance of $60,439. Accrued interest was $4,387 as of March 31, 2016. On May 6, 2015, the Company issued a convertible note payable in the amount of $10,500. The note bears 8% interest and is due on February 8, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the thirty (30) trading day period ending on the latest complete trading day prior to the conversion date. The Company incurred a default fee of $5,250, leaving a balance of $15,750 as of March 31, 2016. The Company is in default on the balance of this note. On May 27, 2015, the Company issued a convertible note payable in the amount of $16,500. The note bears 8% interest rate and is due on May 28, 2016. The loan becomes convertible on May 27, 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $16,500 in principal and $344 in accrued interest into 2,591,323 shares of common stock leaving a remaining balance of $0. On August 28, 2015, the Company issued a convertible note payable in the amount of $15,000. The note bears 8% interest and is due on August 28, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of March 31, 2016 is $15,000, and i On September 4, 2015, the Company issued a convertible note payable in the amount of $19,000. The note bears 8% interest and is due on June 4, 2016. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 55% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the fifteen (15) trading day period ending on the latest complete trading day prior to the conversion date. The loan balance as of March 31, 2016 is $19,000, and On December 29, 2015, the Company issued a convertible note payable in the amount of $57,378. The note bears 8% interest rate and is due on December 30, 2016. The loan becomes convertible on , 2015, the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $59,934 in principal and $1,222 in accrued interest into 35,927,887 shares of common stock, and incurred a default penalty of $4,165, leaving a remaining balance of $1,609. On January 22, 2016, the Company issued a convertible note payable in the amount of $60,500. The note bears 10% interest and is due on October 22, 2016. The loan becomes convertible on January 22, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the average of the lowest two (2) trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date. Interest accrued as of March 31, 2016 is $1,144. On February 25, 2016, the Company issued a convertible note payable in the amount of $27,500. The note bears 8% interest rate and is due on February 25, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. During the period ending March 31, 2016 the note holder converted $5,315 in principal into 11,682,000 shares of common stock leaving a remaining balance of $27,500. On March 24, 2016, the Company issued a convertible note payable in the amount of $7,500. The note bears 8% interest rate and is due on March 24, 2017. The loan becomes convertible on , the issue date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 65% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the twelve (12) trading day period ending on the latest complete trading day prior to the conversion date. .

Derivative Liabilities

Derivative Liabilities	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Notes to Financial Statements
Derivative Liabilities	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the periods ending December 31, 2016 and March 31, 2016: $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $33,000 note dated January 9, 2015; $54,000 note dated February 5, 2015; $66,780 note dated February 17, 2015;$58,300 note dated March 2, 2015; $55,000 note dated March 9, 2015; $29,680 note dated March 26, 2015; $68,900 note dated May 5, 2015; $10,500 note dated May 6, 2015; $16,500 note dated May 27, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015; $55,000 note dated December 29, 2015; $60,500 note dated January 22, 2016; $27,500 note dated February 25, 2016; $7,500 note dated March 24, 2016; $30,000 note dated May 25, 2016; $84,250 note dated June 8, 2016; $56,000 note dated June 23, 2016. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended December 31, 2016, the Company recorded a total change in the fair market value of the derivative liabilities of $83,946. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0001, exercise price of $0.00005 - $0.00058, dividend yield of zero, years to maturity of 0.090410 – .728770, a risk free rate of 0.51% - 0.62%, and annualized volatility of 331% - 529%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370, the May 5, 2015 loan which had an initial debt discount of $41,222, and the May 27, 2015 loan which had an initial debt discount of $15,000. Based on the valuations on the initial valuation dates for the period ending December 31, 2016, the Company recognized debt discounts related to the conversion features totaling $105,366 and a derivative expense of $170,250 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of December 31, 2016, unamortized debt discount, including original issue discounts totaled $130,631. The derivative liabilities totaled $618,060 as of December 31, 2016, of which $- related to long-term debt.	In accordance with AC 815, the Company has bifurcated the conversion feature of their convertible notes and recorded a derivative liability on the date each note became convertible. The derivative liability was then revalued on each reporting date. As detailed in Note 7 (above) the Company has issued several convertible notes in varying amounts and terms, with the following loans becoming convertible during the years ending March 31, 2015 and 2016: $37,500 note dated March 11, 2014; $53,000 note dated April 8, 2014; $42,500 note dated May 21, 2014; $55,000 note dated September 23, 2014; $66,780 note dated August 14, 2014; $58,300 note dated August 14, 2014; $64,500 note dated September 18, 2014; $58,300 note dated March 2, 2015; $61,111 note dated August 13, 2014; $57,895 note dated August 19, 2014; $33,333 note dated December 16, 2014; $27,778 note dated February 25, 2015; $33,000 noted dated October 6, 2014; $55,000 note dated November 6, 2014; $43,000 note dated November 25, 2014; $68,900 note dated May 5, 2015; $16,500 note dated May 27, 2015; $10,500 note dated May 6, 2015; $15,000 note dated August 28, 2015; $19,000 note dated September 4, 2015; $55,000 note dated December 29, 2015; $60,500 note dated January 22, 2016; $27,500 note dated February 25, 2016; and $7,500 note dated March 24, 2016. ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with the above convertible debt. During the period ended March 31, 2016, the Company recorded a total change in the fair market value of the derivative liabilities of $563,432. The Company uses the Black-Scholes option pricing model to value the derivative liability upon the initial conversion date and at each reporting period. Included in the model to value the derivative liabilities of the above loans are the following assumptions: stock price at valuation date of $0.0006, exercise price of $0.000055 - $0.000582, dividend yield of zero, years to maturity of 0.0986 – .9808, a risk free rate of 0.21% - 0.59%, and annualized volatility of 297% - 489%. The above loans were all discounted in full with the exception of the March 2, 2015 loan which had a debt discount of $46,370, the May 5, 2015 loan which had an initial debt discount of $41,222, and the May 27, 2015 loan which had an initial debt discount of $15,000. Based on the valuations on the initial valuation dates, the Company recognized debt discounts related to the conversion features totaling $531,638 and a derivative expense of $497,213 related to the excess value of the derivative liabilities. Once the loans are fully converted, the remaining derivative liability is reclassified to equity as additional paid-in capital. As of March 31, 2016, unamortized debt discount, including original issue discounts totaled $88,365. The derivative liabilities totaled $446,912 as of March 31, 2016, of which $0 related to long-term debt.

Equity Transactions

Equity Transactions	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Equity Transactions
Equity Transactions	The Company has 4,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 827,670 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 5,002,554 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares from 900,000 to 375,030,000. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On June 9, 2015, the Company issued 900,000 units at $0.02 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.02 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 15, 2015, the Company issued 4,000,000 units at $0.01 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.01 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date June 9, 2015 Dec 15,2015 Warrants 900,000 4,000,000 Stock price on grant date $0.02 $0.01 Exercise price $0.02 $0.01 Expected life 5 year 5 year Volatility 98% 98% Risk-free rate 1.74% 1.71% Calculated value $13,259 $29,612 Fair value allocation of proceeds $13,259 $29,612 The following is a summary of the warrant activity for the period March 31, 2016 to December 31, 2016: Number of warrants Weighted average exercise price Outstanding, March 31, 2016 4,930,666 $0.192 Granted $ - Exercised - - Outstanding, December 31, 2016 4,930,666 $0.192 On April 22, 2015, the Company sold 100,381 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable. On June 25, 2015, the Company sold 1,542,455 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company. On July 7, 2015, the Company sold 1,619,423 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services. On July 15, 2015, the Company sold 1,439,282 shares of common stock for $10,075 in cash. On October 27, 2015, the Company sold 1,648,840 shares of common stock for $11,542 in cash. During the periods ended December 31, 2016 and March 31, 2016, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 411,111 $0.04050 April 6, 2015 $10,000 209,644 $0.04770 April 8, 2015 $15,309 453,561 $0.03375 April 8, 2015 $20,001 454,545 $0.04400 April 9, 2015 $14,320 325,455 $0.04400 April 14, 2015 $10,000 236,967 $0.04220 April 16, 2015 $1,918 53,000 $0.03619 April 21, 2015 $10,000 259,740 $0.03850 April 29, 2015 $15,000 389,610 $0.03850 May 4, 2015 $5,083 131,464 $0.03866 May 12, 2015 $28,456 903,380 $0.03150 May 20, 2015 $20,199 947,645 $0.02131 May 20, 015 $17,240 783,636 $0.02200 May 27, 2015 $13,568 701,801 $0.01933 May 29, 2015 $15,000 882,353 $0.01700 June 11, 2015 $9,897 942,609 $0.01050 June 16, 2015 $14,100 1,175,000 $0.01200 June 16, 2015 $13,565 1,130,417 $0.01200 June 22, 2015 $7,415 1,235,833 $0.00600 June 22, 2015 $14,384 2,479,924 $0.00580 June 23, 2015 $7,752 1,292,000 $0.00600 September 16, 2015 $7,974 1,772,033 $0.00450 September 28, 2015 $10,000 1,666,667 $0.00600 September 29, 2015 $10,620 1,770,000 $0.00600 October 7, 2015 $2,250 375,000 $0.00600 October 7, 2015 $8,400 1,400,000 $0.00600 October 19, 2015 $9,720 1,620,000 $0.00600 November 2, 2015 $4,424 1,966,124 $0.00225 November 23, 2015 $10,000 1,666,667 $0.00600 November 30, 2015 $16,844 2,591,323 $0.00650 December 9, 2015 $1,746 775,991 $0.00225 December 17, 2015 $5,332 919,319 $0.00580 December 28, 2015 $1,341 596,200 $0.00225 December 28, 2015 $17,700 2,950,000 $0.00600 December 28, 2015 $14,305 2,384,167 $0.00600 December 28, 2015 $14,963 2,579,916 $0.00580 December 29, 2015 $8,395 1,399,167 $0.00600 December 29, 2015 $7,670 1,278,333 $0.00600 December 30, 2015 $6,651 2,956,248 $0.00225 January 1, 2016 $28,500 4,384,615 $0.00650 January 4, 2016 $19,339 3,223,213 $0.00600 January 5, 2016 $8,107 3,603,227 $0.00225 January 6, 2016 $16,070 2,678,333 $0.00600 January 6, 2016 $16,597 2,861,607 $0.00580 February 16 ,2016 $1,424 4,220,400 $0.00034 February 17, 2016 $12,800 8,443,272 $0.00152 February 23, 2016 $4,640 4,218,182 $0.00110 February 23, 2016 $3,086 4,200,871 $0.00073 February 24, 2016 $1,492 4,419,970 $0.00034 February 25, 2016 $3,000 2,638,987 $0.00114 February 25, 2016 $4,640 4,218,182 $0.00110 March 1, 2016 $1,313 5,834,458 $0.00022 March 2, 2016 $4,600 5,831,643 $0.00079 March 2, 2016 $1,650 2,586,410 $0.00064 March 2, 2016 $9,332 11,650,000 $0.00080 March 7, 2016 $2,799 6,546,292 $0.00043 March 11, 2016 $1,924 4,147,500 $0.00046 March 14, 2016 $2,245 7,125,777 $0.00032 March 15, 2016 $3,329 7,454,098 $0.00045 March 15, 2016 $5,210 11,450,000 $0.00046 March 22, 2016 $2,419 8,957,888 $0.00027 March 22, 2016 $2,367 7,200,486 $0.00033 March 22, 2016 $5,315 11,682,000 $0.00046 March 28, 2016 $1,986 8,958,779 $0.00022 March 31, 2016 Total $602,376 194,603,040 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 9,766,311 $0.000225 April 4, 2016 $4,847 17,250,000 $0.000281 April 7, 2016 $1,750 9,722,222 $0.000180 April 14, 2016 $4,158 19,250,000 $0.000216 April 15, 2016 $1,318 9,766,222 $0.000135 April 26, 2016 $1,705 12,629,776 $0.000135 May 4, 2016 $2,067 9,718,025 $0.000213 May 31, 2016 $ 828 4,600,055 $0.000180 June 2, 2016 $9,120 30,000,000 $0.000304 June 2, 2016 $4,401 29,340,333 $0.000150 June 14, 2016 $5,847 29,235,900 $0.000200 June 17,2016 $5,691 28,456,150 $0.000200 June 29, 2016 $6,580 21,270,355 $0.000309 August 23, 2016 $2,567 22,129,741 $0.000116 August 29, 2016 $2,570 22,156,120 $0.000116 September 6, 2016 $2,547 21,952,672 $0.000116 September 20, 2016 $2,443 25,267,655 $0.000097 September 26, 2016 $2,946 25,393,448 $0.000116 September 28, 2016 $2,947 25,403,448 $0.000116 September 30, 2016 $3,949 51,066,724 $0.000077 October 7, 2016 $3,381 58,291,551 $0.000058 October 14, 2016 $3,380 58,275,689 $0.000058 October 21, 2016 $3,385 58,355,689 $0.000058 October 26, 2016 $3,382 58,316,551 $0.000058 October 31, 2016 $5,037 86,837,068 $0.000058 November 7 , 2016 $5,015 86,472,931 $0.000058 November 22, 2016 $5,513 95,060,172 $0.000058 November 29, 2016 $5,515 95,092,931 $0.000058 December 6, 2016 $4,058 69,959,310 $0.000058 December 31, 2016 Total $109,144 1,091,037,049 (2) Effective April 6, 2015, the Company approved the re-pricing of all 2,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.17 per share, to $0.08 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 3,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.02 per share, to $0.02 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. On February 8, 2016, the Company approved a change in the authorized shares of common stock to 4,000,000,000 shares. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. During the year ended March 31, 2014, the Company granted 475,033 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 672,533 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.91984 per share and $30.0 per share, to $0.17 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date April 6, 2015 June 9, 2015 December 15, 2015 Options 2,040,003 1,000,000 860,000 Stock price grant date $0.08 $0.02 $0.01 Initial Exercise price $0.08 $0.02 $0.01 Modified Exercise price $0.01 $0.01 $0.01 Expected life 5.0 5.0 5.0 Volatility 99% 99% 84% Risk-free rate 1.31% 1.74% 1.70% Calculated value $120,778 $14,838 $5,736 Modified value $151,221 $16,347 $5,736 The following is a summary of the option activity for the period March 31, 2015 through December 31, 2016: Number of options Weighted average exercise price Outstanding, March 31, 2015 672,533 $0.01 Granted 3,900,003 $0.01 Exercised - - Expired - - Outstanding, December 31, 2016 4,572,536 $0.01	The Company has 4,000,000,000 common shares authorized with a par value of $ 0.001 per share. The Company has 10,000,000 preferred shares authorized with a par value of $ 0.001 per share. On July 18, 2013, the Company designated, from the 10,000,000 authorized shares of preferred stock, 6,000,000 shares of Series “A” Preferred Stock. The Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company granted 6,000,000 Series “A” Preferred shares and 827,670 common shares for the intellectual property. The common and preferred shares were valued at a total of $123,973. On July 19, 2013, our new officer/director agreed to cancel 5,002,554 common shares and returned them to treasury. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares from 900,000 to 375,030,000. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. On October 29, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 11, 2013, the Company granted 2,500 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On March 10, 2014, the Company issued 833 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 2,500 2,500 833 Stock price on grant date $30.00 $2.00 $2.00 Exercise price $50.00 $50.00 $50.00 Expected life 1 year 1 year 1 year Volatility 147% 64% 65% Risk-free rate 0.12% 0.11% 0.13% Calculated value $10,473 $0 $0 Fair value allocation of proceeds $7,381 $0 $0 On April 4, 2014, the Company issued 833 units at $30.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $50.00 and a one year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On April 24, 2014, the Company issued 10,000 units at $25.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $35.00 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 10, 2014, the Company issued 7,000 units at $4.30 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $15.00 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On July 29, 2014, the Company issued 7,000 units at $5.00 per unit. Each unit consisted of 1 share of common stock and one common stock warrant with an exercise price of $15.00 and a three year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On June 9, 2015, the Company issued 900,000 units at $0.02 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.02 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. On December 15, 2015, the Company issued 4,000,000 units at $0.01 per unit. Each unit consisted of one common stock warrant with an exercise price of $0.01 and a five year term. The value of the warrants was derived by using the Black-Scholes valuation model. A summary of the valuation inputs is below. The following is a summary of the inputs used to determine the value of the warrants issued in connection with common stock using the Black-Scholes option pricing model. Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Dec 15,2015 Warrants 833 10,000 7,000 7,000 900,000 4,000,000 Stock price on grant date $19.90 $25.20 $3.70 $3.70 $0.02 $0.01 Exercise price $50.00 $35.00 $15.00 $15.00 $0.02 $0.01 Expected life 1 year 3 year 3 year 3 year 5 year 5 year Volatility 113% 76% 119% 119% 98% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% 1.71% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 $29,612 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259 $29,612 The following is a summary of the warrant activity for the period from April 1, 2013 to March 31, 2016: Number of warrants Weighted average exercise price Outstanding, March 31, 2014 5,833 $50.00 Granted 24,833 $24.00 Exercised - - Outstanding, March 31, 2015 30,666 $29.00 Granted 4,900,000 $0.012 Exercised - - Outstanding, March 31, 2016 4,930,666 $0.192 On May 7, 2014, the Company granted 25,000 shares to a consultant for prior services rendered. The Company had accrued $300,000 for these services as of March 31, 2014. On June 16, 2014, the Company issued 14,690 shares of common stock for stock deposits of $147,050. The Company had received the deposits during the year ended March 31, 2014. On July 1, 2014, the Company granted 10,000 shares to a professional for prior legal services rendered. The Company had accrued $30,000 for these services as of June 30, 2014. The shares were valued on the grant date at the fair market value of $60,000 resulting in a loss on the issuance of shares of $30,000. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC, a related party, and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value of $7,822,235 as a deemed dividend reducing additional paid in capital. Also on October 6, 2014, the Board of Directors approved the issuance of 80,000 shares of common stock to the CEO and 40,000 shares of common stock to the Company’s attorney as bonuses. The shares were valued based on the closing stock price on the grant date for a total value of $429,600. On November 19, 2014, the Company entered into an agreement with an unrelated vendor to provide six months of consulting services in exchange for 5,000 shares of common stock. The shares were valued based on the closing stock price on the grant date for a total value of $6,450. The entire contract was expensed as of March 31, 2015. On August 13, 2014, the Company entered into an investment agreement with an investor to invest up to $4,000,000 to purchase the Company’s common stock. The price per share for each investment is determined by the lesser of: (1) 65% of the lowest traded price of the Company’s common stock during the ten consecutive trading days prior to the drawdown notice date or (2) 65% of the closing bid price on the day before the drawdown notice is submitted. During the year ended March 31, 2015, the Company issued 799,619 shares of common stock to this investor for total proceeds of $220,000. On April 22, 2015, the Company sold 100,381 shares of common stock for $5,405 in cash, which was paid directly to a vendor for accounts payable. On June 25, 2015, the Company sold 1,542,455 shares of common stock for $10,797 in cash, of which $3,750 was paid directly to professionals in connection with the expenses of that sale, and $7,047 was retained by the Company. On July 7, 2015, the Company sold 1,619,423 shares of common stock for $11,336 in cash, of which $3,750 was paid directly to a vendor for professional services. On July 15, 2015, the Company sold 1,439,282 shares of common stock for $10,075 in cash. On October 27, 2015, the Company sold 1,648,840 shares of common stock for $11,542 in cash. During the years ended March 31, 2016 and, 2015, the Company received, as listed, conversion notices from various note holders. The Company issued the following common shares to satisfy the conversion of the following debt and interest: Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $ 12,000 5,505 $ 2.18 October 1, 2014 $ 12,000 6,487 $ 1.85 October 8, 2014 $ 9,000 5,056 $ 1.78 October 16, 2014 $ 6,000 4,546 $ 1.32 October 29, 2014 $ 15,000 12,500 $ 1.20 November 3, 2014 $ 10,000 8,197 $ 1.22 November 7, 2014 $ 12,000 11,881 $ 1.01 November 19, 2014 $ 18,120 28,312 $ 0.64 December 8, 2014 $ 15,000 34,884 $ 0.43 December 15, 2014 $ 12,000 42,857 $ 0.28 December 26, 2014 $ 17,200 74,783 $ 0.23 February 11, 2015 $ 29,900 747,500 $ 0.04 February 12, 2015 $ 17,333 373,561 $ 0.046 February 13, 2015 $ 17,894 372,800 $ 0.048 February 15, 2015 $ 35,730 739,243 $ 0.048 February 17, 2015 $ 17,003 366,440 $ 0.046 February 23, 2015 $ 20,603 470,900 $ 0.044 February 23, 2015 $ 17,003 366,440 $ 0.046 February 24, 2015 $ 9,488 204,473 $ 0.046 February 26, 2015 $ 42,030 1,050,750 $ 0.040 February 27, 2015 $ 26,880 560,000 $ 0.048 March 2, 2015 $ 56,402 1,215,551 $ 0.046 March 9, 2015 $ 33,900 475,182 $ 0.071 March 10, 2015 $ 25,200 700,000 $ 0.036 March 20, 2015 $ 10,000 181,818 $ 0.006 March 31, 2015 Total $ 498,686 8,059,666 On February 8, 2016, the Company approved a change in the authorized shares of common stock to 375,030,000 shares. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods. Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $ 16,650 411,111 $ 0.04050 April 6, 2015 $ 10,000 209,644 $ 0.04770 April 8, 2015 $ 15,309 453,561 $ 0.03375 April 8, 2015 $ 20,001 454,545 $ 0.04400 April 9, 2015 $ 14,320 325,455 $ 0.04400 April 14, 2015 $ 10,000 236,967 $ 0.04220 April 16, 2015 $ 1,918 53,000 $ 0.03619 April 21, 2015 $ 10,000 259,740 $ 0.03850 April 29, 2015 $ 15,000 389,610 $ 0.03850 May 4, 2015 $ 5,083 131,464 $ 0.03866 May 12, 2015 $ 28,456 903,380 $ 0.03150 May 20, 2015 $ 20,199 947,645 $ 0.02131 May 20, 015 $ 17,240 783,636 $ 0.02200 May 27, 2015 $ 13,568 701,801 $ 0.01933 May 29, 2015 $ 15,000 882,353 $ 0.01700 June 11, 2015 $ 9,897 942,609 $ 0.01050 June 16, 2015 $ 14,100 1,175,000 $ 0.01200 June 16, 2015 $ 13,565 1,130,417 $ 0.01200 June 22, 2015 $ 7,415 1,235,833 $ 0.00600 June 22, 2015 $ 14,384 2,479,924 $ 0.00580 June 23, 2015 $ 7,752 1,292,000 $ 0.00600 September 16, 2015 $ 7,974 1,772,033 $ 0.00450 September 28, 2015 $ 10,000 1,666,667 $ 0.00600 September 29, 2015 $ 10,620 1,770,000 $ 0.00600 October 7, 2015 $ 2,250 375,000 $ 0.00600 October 7, 2015 $ 8,400 1,400,000 $ 0.00600 October 19, 2015 $ 9,720 1,620,000 $ 0.00600 November 2, 2015 $ 4,424 1,966,124 $ 0.00225 November 23, 2015 $ 10,000 1,666,667 $ 0.00600 November 30, 2015 $ 16,844 2,591,323 $ 0.00650 December 9, 2015 $ 1,746 775,991 $ 0.00225 December 17, 2015 $ 5,332 919,319 $ 0.00580 December 28, 2015 $ 1,341 596,200 $ 0.00225 December 28, 2015 $ 17,700 2,950,000 $ 0.00600 December 28, 2015 $ 14,305 2,384,167 $ 0.00600 December 28, 2015 $ 14,963 2,579,916 $ 0.00580 December 29, 2015 $ 8,395 1,399,167 $ 0.00600 December 29, 2015 $ 7,670 1,278,333 $ 0.00600 December 30, 2015 $ 6,651 2,956,248 $ 0.00225 January 1, 2016 $ 28,500 4,384,615 $ 0.00650 January 4, 2016 $ 19,339 3,223,213 $ 0.00600 January 5, 2016 $ 8,107 3,603,227 $ 0.00225 January 6, 2016 $ 16,070 2,678,333 $ 0.00600 January 6, 2016 $ 16,597 2,861,607 $ 0.00580 February 16 ,2016 $ 1,424 4,220,400 $ 0.00034 February 17, 2016 $ 12,800 8,443,272 $ 0.00152 February 23, 2016 $ 4,640 4,218,182 $ 0.00110 February 23, 2016 $ 3,086 4,200,871 $ 0.00073 February 24, 2016 $ 1,492 4,419,970 $ 0.00034 February 25, 2016 $ 3,000 2,638,987 $ 0.00114 February 25, 2016 $ 4,640 4,218,182 $ 0.00110 March 1, 2016 $ 1,313 5,834,458 $ 0.00022 March 2, 2016 $ 4,600 5,831,643 $ 0.00079 March 2, 2016 $ 1,650 2,586,410 $ 0.00064 March 2, 2016 $ 9,332 11,650,000 $ 0.00080 March 7, 2016 $ 2,799 6,546,292 $ 0.00043 March 11, 2016 $ 1,924 4,147,500 $ 0.00046 March 14, 2016 $ 2,245 7,125,777 $ 0.00032 March 15, 2016 $ 3,329 7,454,098 $ 0.00045 March 15, 2016 $ 5,210 11,450,000 $ 0.00046 March 22, 2016 $ 2,419 8,957,888 $ 0.00027 March 22, 2016 $ 2,367 7,200,486 $ 0.00033 March 22, 2016 $ 5,315 11,682,000 $ 0.00046 March 28, 2016 $ 1,986 8,958,779 $ 0.00022 March 31, 2016 Total $ 602,376 194,603,040 The Company accounts for employee stock-based compensation in accordance with the guidance of ASC Topic 718: Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values. The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options issued as compensation for services provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option, whichever can be more clearly determined. During the year ended March 31, 2014, the Company granted 475,033 stock options to officers, directors, employees and consultants. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants The options have been re-priced twice as follows: (1) Effective January 12, 2015, the Company approved the re-pricing of all 672,533 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $1.91984 per share and $30.0 per share, to $0.17 per share which was the closing price of the Company’s common stock on January 9, 2015. All of the other terms of the options remained unchanged. (2) Effective April 6, 2015, the Company approved the re-pricing of all 2,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.17 per share, to $0.08 per share which was the closing price of the Company’s common stock on April 6, 2015. All of the other terms of the options remained unchanged. (3) Effective August 4, 2015, the Company approved the re-pricing of all 3,712,535 previously granted options under the Company’s 2013 Equity Incentive Plan, which had exercise prices between $.08 per share and $0.02 per share, to $0.02 per share which was the closing price of the Company’s common stock on August 4, 2015. All of the other terms of the options remained unchanged. The Company revalued all existing options on January 12, 2015 and again on April 6, 2015, and again on August 4, 2015 using the Black-Scholes option pricing model using the initial terms of the options and the modified terms of the options. The difference in the valuations was recorded as additional expense. The re-pricing of the options resulted in the recognition of an additional $50,448 on January 9, 2015 and an additional $9,316 on April 6, 2015, and an additional $47,463 on August 4, 2015 in related stock based compensation expense for those periods. The following is a summary of the inputs used to determine the value of the options using the Black-Scholes option pricing model. Date May 7, 2014 July 23, 2014 October 6, 2014 April 6, 2015 June 9, 2015 December 15, 2015 Options 35,000 7,500 155,000 2,040,003 1,000,000 860,000 Stock price grant date $12.00 $6.90 $3.58 $0.08 $0.02 $0.01 Initial Exercise price $12.00 $6.90 $1.91984 $0.08 $0.02 $0.01 Modified Exercise price $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 Expected life 10.00 10.00 5.0 5.0 5.0 5.0 Volatility 73% 88% 101% 99% 99% 84% Risk-free rate 2.56% 2.53% 1.04% 1.31% 1.74% 1.70% Calculated value $315,772 $45,109 $454,798 $120,778 $14,838 $5,736 Modified value $7,164 $1,537 $31,408 $151,221 $16,347 $5,736 The following is a summary of the option activity for the period April 1, 2013 through March 31, 2016: Number of options Weighted average exercise price Outstanding, March 31, 2014 475,033 $0.01 Granted 197,500 $0.01 Exercised - - Expired - - Outstanding, March 31, 2015 672,533 $0.01 Granted 3,900,003 $0.01 Exercised - - Expired - - Outstanding, March 31, 2016 4,572,536 $0.01

Commitments and Contigencies

Commitments and Contigencies	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Commitments and Contingencies	The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800. On July 8, 2016, the Company engaged a foreign based company to evaluate the safety and efficacy of RP-323 over a 27 month period. The contract stipulates a commitment of $193,255 with additional fees for pass-through expenses. The inventor of the intellectual property which was assigned to Rich Pharmaceuticals, Inc. in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court. The Company incurred substantial fees in defending the litigation.	The Company leases office space on a verbal month-to-month agreement. Monthly rent is approximately $2,800. The inventor of the intellectual property which was assigned to the Company in July 2013 by Imagic, LLC and Richard L. Chang’s Holdings, LLC is presently in declaratory relief litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”), a company who was previously assigned licensing rights in the intellectual property. In connection with this litigation, on January 17, 2014, the Company received notice of a complaint filed by Biosuccess against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (our CEO and a director) in the United States District Court, Central District of California Western Division (the “District Court”). The Complaint includes allegations of patent and copyright infringement, misappropriation of trade secrets, breach of fiduciary duty, unfair competition and other causes of actions against the Company, Imagic, LLC, Richard L. Chang’s Holdings, LLC, and Ben Chang (the “Litigation”). The Complaint seeks relief which includes compensatory damages, attorneys’ fees and costs, an award of treble damages, and such other relief as the court may deem just and proper. As previously disclosed on January 4, 2016, the Litigation has been settled through a confidential mediation process supervised by the Federal Court and the Litigation has been dismissed with prejudice by the Federal Court .

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.	The Company has a working capital deficit, has not yet received revenues from sales of products or services, and has incurred losses since inception. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	As of March 31, 2016, the Company had net operating loss carry forwards of approximately $9,203,440 that may be available to reduce future years’ taxable income in varying amounts through 2033. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The provision for Federal income tax consists of the following for the years ended March 31, 2016 and 2015: March 31, 2016 March 31, 2015 Federal income tax benefit attributable to: Current operations $ 601,276 $ 1,405,416 Less: valuation allowance (601,276 ) (1,405,416 ) Net provision for Federal income taxes $ — $ — The cumulative tax effect at the expected rate of 34% of significant items comprising our net deferred tax amount is as follows as of March 31, 2016 and 2015: March 31, 2016 March 31, 2015 Deferred tax asset attributable to: Net operating loss carryover $ 3,129,170 $ 2,454,951 Less: valuation allowance (3,129,170 ) (2,454,951 ) Net deferred tax asset $ — $ — Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of approximately $9,395,636 for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Subsequent Events	On January 10, 2017, the Company converted $6,000 in principle and $301 in interest on a convertible note payable into 126,023,000 shares of common stock. On January 5, 2017, the Company issued a Convertible Redeemable Promissory Note with possible funding up to the principal amount of $335,000. The first tranche of $80,000 to be received on January 5, 2017, with a subsequent tranche of $20,000 one week later, any additional tranches will be made at the time and in the amount that is the discretion of the investor. The note bears interest at the rate of 10% and must be repaid on or October 5, 2017. The note and any accrued interest may be converted by lender into shares of Company common stock, upon issuance, In accordance with ASC 855-10, the Company has analyzed its operations subsequent to December 31, 2016 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.	Effective May 23, 2016, the Board of Directors of Rich Pharmaceuticals, Inc. approved an increase in authorized common stock to 4,000,000,000. On April 1, 2016 the Company converted $2,158 in principle and $39 in accrued interest into 9,766,311 shares of common stock in satisfaction of the terms of a convertible loan. On April 4, 2016 the Company converted $4,847 in principle into 17,250,000 shares of common stock in satisfaction of the terms of a convertible loan. On April 7, 2016 the Company converted $1,699 in principle and $51 in accrued interest into 9,722,222 shares of common stock in satisfaction of the terms of a convertible loan. On April 14, 2016 the Company converted $4,158 in principle into 19,250,000 shares of common stock in satisfaction of the terms of a convertible loan. On April 15, 2016 the Company converted $1,259 in principle and $59 in accrued interest into 9,766,222 shares of common stock in satisfaction of the terms of a convertible loan. On May 25, 2016, the Company issued a convertible note payable in the amount of $30,000. The note bears 8% interest and is due on May 25, 2017. The loan becomes convertible 180 days after issuance or November 21, 2016. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 50% multiplied by the market price, which is the lowest trading prices for the common stock during the twenty (20) trading day period ending on the latest complete trading day prior to the conversion date . On May 31, 2016, the Company executed a Secured Promissory Note in in favor of Computerlaw Group, LLP. The Note was also executed by Ben Chang, the CEO and a director of the Company, and his father Richard Chang, who with the Company are jointly and severally liable for repayment of the Note. The Note accrues interest at the rate of 10% and is due and payable on August 1, 2017, and may be paid at a reduced amount if paid early. The Note relates to payment terms provided by Computerlaw Group, LLP regarding the outstanding account payable by the Company to them for their defense in the litigation with Biosuccess Biotech, Co. LTD. (“Biosuccess”). On May 31, 2016 the Company converted $828 in principle into 4,600,055 shares of common stock in satisfaction of the terms of a convertible loan. On June 3, 2016 the Company converted $4,401 in principle into 29,340,333 shares of common stock in satisfaction of the terms of a convertible loan. On June 7, 2016 the Company converted $9,120 in principle into 30,000,000 shares of common stock in satisfaction of the terms of a convertible loan. On June 9, 2016, the Company completed a financing pursuant to a Securities Purchase Agreement (the “SPA”), an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250 (the “First Note”), and an 8% Convertible Redeemable Promissory Note in the principal amount of $84,250 (the “Second Note”). The First and Second Note each bear interest at the rate of 8% and must be repaid on or June 8, 2017. The First Note and Second Note may be converted into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion (as determined in the First Note and Second Note). The Second Note was initially paid for by the issuance of an offsetting $84,250 secured note issued to the Company provided that prior to conversion of the Second Note, the lender must have paid off the note in cash such that the Second Note may not be converted until it has been paid for in cash. The SPA, First Note and Second Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the First Note and Second Note in the event of such defaults. On June 14, 2016 the Company converted $5,847 in principle into 29,235,900 shares of common stock in satisfaction of the terms of a convertible loan On June 17, 2016 the Company converted $5,691 in principle into 28,456,150 shares of common stock in satisfaction of the terms of a convertible loan On June 25, 2016, the Company completed a financing pursuant to a Securities Purchase Agreement (the “SPA”), an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000 (the “First Note”), and an 8% Convertible Redeemable Promissory Note in the principal amount of $56,000 (the “Second Note”). The First and Second Note each bear interest at the rate of 8% and must be repaid on or June 23, 2017. The First Note and Second Note may be converted by lender into shares of Company common stock at a conversion price equal to 50% of the lowest trading price during the 20-day period prior to conversion (as determined in the First Note and Second Note). The Second Note was initially paid for by the issuance of an offsetting $56,000 secured note issued to the Company by lender, provided that prior to conversion of the Second Note, lender must have paid off the Note in cash such that the Second Note may not be converted until it has been paid for in cash. The SPA, First Note and Second Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the First Note and Second Note in the event of such defaults. The Company also executed a Confession of Judgment in favor of lender regarding any event of default occurring under the First Note, the Second Note and all other convertible promissory notes issued by the Company and held by LG. On June 25, 2016, the Company executed a Confession of Judgment in favor of LG regarding any event of default occurring under the convertible promissory notes issued by the Company and held by LG. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2016 to the date these financial statements were issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described above.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Nature of Business	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.	On August 9, 2010 the Company was incorporated as Nepia Inc. in the State of Nevada. From August 9, 2010 to July 18, 2013, the Company was in the business of developing, manufacturing, and selling small boilers aimed at farmers primarily in Southeast Asia. Beginning on July 19, 2013, the Company acquired bio-pharmaceutical intellectual property for the treatment of acute myeloid leukemia (AML) and is entering into phase II human studies. The goal is to perfect this indication for marketing purposes for distribution world-wide. On August 26, 2013, as a consequence of our new business direction, the Company changed its name to Rich Pharmaceuticals, Inc. (“Rich” or “the Company”). On July 18, 2013, the Company designated, from our 10,000,000 authorized shares of preferred stock, par value $0.001, 6,000,000 shares of Series “A” Preferred Stock. Our Series “A” Preferred Stock has voting rights of 100 votes per share and votes with common shares as a single class. On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares, and 6,000,000 Series “A” Preferred shares. The common and preferred shares were valued at $123,973. The Company further agreed to use its best efforts to complete a financing resulting in proceeds of at least $2,000,000. If the Company was unable to raise $400,000 according to the terms of the Assignment Agreement, the patent reverts back to Imagic, LLC and its principals. On January 17, 2014, the right of reversion was terminated in exchange for a payment of $20,000. On July 19, 2013, the Company entered into an Agreement of Conveyance, Transfer and Assignment of Assets and Assumption of Obligations (the “Sale Agreement”) with our prior officers and directors. Pursuant to the Sale Agreement, the Company transferred all assets and business operations associated with our boiler business in exchange for assumption of all obligations associated with that business and cancellation of loans amounting to $28,818. The cancellation of debt was recorded as additional paid-in capital. In consequence to the Sale Agreement two former officers sold 5,312,925 common shares held by them to our new officer/director. In turn, our new officer/director agreed to cancel 5,002,554 of those shares he received and returned them to treasury for retirement. Certain other shareholders also agreed to cancel 2,625,210 common shares. On September 5, 2013, the Company increased the authorized common shares, par value $0.0010, from 900,000 shares to 375,030,000 shares. Correspondingly, the Company affirmed a forward split of 4.167 for 1 in which each shareholder was issued 4.167 common shares for each share held. All share and per share date included in these financial statements has been retrospectively adjusted to account for the stock split. Effective February 11, 2016, the Company approved a reverse stock split of the common stock, par value $0.001 per share at a ratio of 1 for 100 of each share issued and outstanding on the effective date. These financial statements retroactively reflect the reverse stock split for all periods.
Cash and Cash Equivalents	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At December 31, 2016 and March 31, 2016 the Company had $- and $-, respectively, of unrestricted cash.	The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. At March 31, 2016 and 2015 the Company had $0 and $15,892, respectively, of unrestricted cash.
Basis of Presentation	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016, as filed with the U.S. Securities and Exchange Commission.	The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015, as filed with the U.S. Securities and Exchange Commission.
Property and Equipment	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.	Property and equipment is recorded at cost and is depreciated using the straight-line method over the estimated useful lives of the related assets. The useful lives of the assets are as follows: Computer equipment, 3 years.
Long-Lived and Intangible Assets	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.	On July 18, 2013, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Phorbol esters as anti-neoplastic and white blood cell elevating agents” and all related intellectual property associated with the patent. In consideration for the intellectual property the Company issued 827,670 common shares and 6,000,000 Series “A” Preferred Stock. These shares were valued at a total of $123,973. The Company has also paid additional funds to third parties to further the development of this asset and terminate the right of reversion totaling $45,000. The Company analyzed the assets at March 31, 2014 and determined that the value could not be supported and impaired the assets to $0. On October 6, 2014, the Company entered into an Asset Assignment Agreement (the “Assignment Agreement”) with Imagic, LLC and its principals to acquire certain assets including a US Patent entitled “Compositions and methods of use of Phorbol Esters for the treatment of Hodgkin’s Lymphoma”, and all related intellectual property, inventions and trade secrets, data and clinical study results. In consideration for the intellectual property the Company issued 2,207,920 common shares. These shares were valued at a total of $7,904,355; however, since the asset was acquired from a related party the Company valued the asset at the cost of the asset to the related party, $82,120, and treated the excess value as a deemed dividend reducing additional paid in capital. The Company analyzed the assets at March 31, 2015 and determined that the value could not be supported and impaired the assets to $0.
Use of Estimates	The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at December 31, 2016 or March 31, 2016. As of December 31, 2016, the derivative liabilities were considered a level 2 item; see Note 8.	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.	The Company’s financial instruments consist of cash and cash equivalents, prepaid expenses, accounts payable, accrued expenses, amounts due to related parties, stock deposits, and a convertible note payable. The carrying amount of these financial instruments approximates fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1 – Observable inputs such as quoted prices in active markets; Level 2 – Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; Level 3 – Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company did not have any level 1 or level 3 financial instruments at March 31, 2016 or 2015. As of March 31, 2016, the derivative liabilities were considered a level 2 item; see Note 8.
Income Taxes	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.	Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.
Revenue Recognition	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.	The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured.
Research and Development	The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.	The Company will charge research and development costs to expense when incurred. The research and development costs include payments made to unrelated third party vendors for their work on enhancements to existing technology, or research into new potentially patentable products or processes.
Stock-Based Compensation	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share.	Stock-based compensation is accounted for at fair value in accordance with ASC Topic 718. On September 6, 2013, the Company approved the adoption of Rich Pharmaceuticals, Inc. 2013 Stock Option/Stock Issuance Plan (the "2013 Plan”). The 2013 Plan is intended to aid in recruiting and retaining key employees, directors or consultants and to motivate them by providing incentives through the granting of awards of stock options or other stock based awards. The 2013 Plan is administered by the board of directors. Directors, officers, employees and consultants and our affiliates are eligible to participate under the 2013 Plan. A total of 3,900,048 common shares have been reserved for awards under the 2013 Plan. During the year ended March 31, 2015, the Company granted 197,500 stock options to officers, directors, employees and consultants. During the period ended March 31, 2016, the Company granted 3,900,003 stock options to officers, directors, employees and consultants. The Company made the following modifications to the exercise prices of its options: January 12, 2015, the Company modified the exercise price on all outstanding stock options to $0.17; April 6, 2015, the Company modified the exercise price on all outstanding stock options to $0.08 per share; August 4, 2015, the Company modified the exercise price on all outstanding stock options to $0.01 per share.
Basic loss per share	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.	The basic earnings (loss) per share is calculated by dividing the Company’s net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company’s net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.
Recent Accounting Pronouncements	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.	The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

Property and equipment (Tables)

Property and equipment (Tables)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	December 31, 2016 March 31, 2016 Computer equipment & furniture $ 5,160 $ 5,160 Less: accumulated depreciation (2,723 ) (1,429 ) Property and equipment, net $ 2,437 $ 3,731	March 31, 2016 March 31, 2015 Computer equipment & furniture $ 5,160 $ 1,419 Less: accumulated depreciation (1,429 ) (631 ) Property and equipment, net $ 3,731 $ 788

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	December 31, 2016 March 31, 2016 Wages and taxes $ 799,711 $ 514,713 Accrued interest 96,903 15,437 Total accrued expenses $ 896,614 $ 530,150	March 31, 2016 March 31, 2015 Wages and taxes $ 514,713 $ 175,357 Accrued interest 15,437 25,534 Total accrued expenses $ 530,150 $ 200,891

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of Value of Warrants	Date June 9, 2015 Dec 15,2015 Warrants 900,000 4,000,000 Stock price on grant date $0.02 $0.01 Exercise price $0.02 $0.01 Expected life 5 year 5 year Volatility 98% 98% Risk-free rate 1.74% 1.71% Calculated value $13,259 $29,612 Fair value allocation of proceeds $13,259 $29,612	Date October 29, 2013 December 11, 2013 March 10, 2014 Warrants 2,500 2,500 833 Stock price on grant date $30.00 $2.00 $2.00 Exercise price $50.00 $50.00 $50.00 Expected life 1 year 1 year 1 year Volatility 147% 64% 65% Risk-free rate 0.12% 0.11% 0.13% Calculated value $10,473 $0 $0 Fair value allocation of proceeds $7,381 $0 $0 Date April 4, 2014 April 24, 2014 July 10, 2014 July 29, 2014 June 9, 2015 Dec 15,2015 Warrants 833 10,000 7,000 7,000 900,000 4,000,000 Stock price on grant date $19.90 $25.20 $3.70 $3.70 $0.02 $0.01 Exercise price $50.00 $35.00 $15.00 $15.00 $0.02 $0.01 Expected life 1 year 3 year 3 year 3 year 5 year 5 year Volatility 113% 76% 119% 119% 98% 98% Risk-free rate 0.12% 0.84% 0.96% 0.98% 1.74% 1.71% Calculated value $3,181 $104,416 $12,130 $12,102 $13,259 $29,612 Fair value allocation of proceeds $2,822 $73,653 $8,637 $8,992 $13,259 $29,612
Schedule of Warrant Activity	Number of warrants Weighted average exercise price Outstanding, March 31, 2016 4,930,666 $0.192 Granted $ - Exercised - - Outstanding, December 31, 2016 4,930,666 $0.192	Number of warrants Weighted average exercise price Outstanding, March 31, 2014 5,833 $50.00 Granted 24,833 $24.00 Exercised - - Outstanding, March 31, 2015 30,666 $29.00 Granted 4,900,000 $0.012 Exercised - - Outstanding, March 31, 2016 4,930,666 $0.192
Schedule of Conversions of Common Stock	Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $16,650 411,111 $0.04050 April 6, 2015 $10,000 209,644 $0.04770 April 8, 2015 $15,309 453,561 $0.03375 April 8, 2015 $20,001 454,545 $0.04400 April 9, 2015 $14,320 325,455 $0.04400 April 14, 2015 $10,000 236,967 $0.04220 April 16, 2015 $1,918 53,000 $0.03619 April 21, 2015 $10,000 259,740 $0.03850 April 29, 2015 $15,000 389,610 $0.03850 May 4, 2015 $5,083 131,464 $0.03866 May 12, 2015 $28,456 903,380 $0.03150 May 20, 2015 $20,199 947,645 $0.02131 May 20, 015 $17,240 783,636 $0.02200 May 27, 2015 $13,568 701,801 $0.01933 May 29, 2015 $15,000 882,353 $0.01700 June 11, 2015 $9,897 942,609 $0.01050 June 16, 2015 $14,100 1,175,000 $0.01200 June 16, 2015 $13,565 1,130,417 $0.01200 June 22, 2015 $7,415 1,235,833 $0.00600 June 22, 2015 $14,384 2,479,924 $0.00580 June 23, 2015 $7,752 1,292,000 $0.00600 September 16, 2015 $7,974 1,772,033 $0.00450 September 28, 2015 $10,000 1,666,667 $0.00600 September 29, 2015 $10,620 1,770,000 $0.00600 October 7, 2015 $2,250 375,000 $0.00600 October 7, 2015 $8,400 1,400,000 $0.00600 October 19, 2015 $9,720 1,620,000 $0.00600 November 2, 2015 $4,424 1,966,124 $0.00225 November 23, 2015 $10,000 1,666,667 $0.00600 November 30, 2015 $16,844 2,591,323 $0.00650 December 9, 2015 $1,746 775,991 $0.00225 December 17, 2015 $5,332 919,319 $0.00580 December 28, 2015 $1,341 596,200 $0.00225 December 28, 2015 $17,700 2,950,000 $0.00600 December 28, 2015 $14,305 2,384,167 $0.00600 December 28, 2015 $14,963 2,579,916 $0.00580 December 29, 2015 $8,395 1,399,167 $0.00600 December 29, 2015 $7,670 1,278,333 $0.00600 December 30, 2015 $6,651 2,956,248 $0.00225 January 1, 2016 $28,500 4,384,615 $0.00650 January 4, 2016 $19,339 3,223,213 $0.00600 January 5, 2016 $8,107 3,603,227 $0.00225 January 6, 2016 $16,070 2,678,333 $0.00600 January 6, 2016 $16,597 2,861,607 $0.00580 February 16 ,2016 $1,424 4,220,400 $0.00034 February 17, 2016 $12,800 8,443,272 $0.00152 February 23, 2016 $4,640 4,218,182 $0.00110 February 23, 2016 $3,086 4,200,871 $0.00073 February 24, 2016 $1,492 4,419,970 $0.00034 February 25, 2016 $3,000 2,638,987 $0.00114 February 25, 2016 $4,640 4,218,182 $0.00110 March 1, 2016 $1,313 5,834,458 $0.00022 March 2, 2016 $4,600 5,831,643 $0.00079 March 2, 2016 $1,650 2,586,410 $0.00064 March 2, 2016 $9,332 11,650,000 $0.00080 March 7, 2016 $2,799 6,546,292 $0.00043 March 11, 2016 $1,924 4,147,500 $0.00046 March 14, 2016 $2,245 7,125,777 $0.00032 March 15, 2016 $3,329 7,454,098 $0.00045 March 15, 2016 $5,210 11,450,000 $0.00046 March 22, 2016 $2,419 8,957,888 $0.00027 March 22, 2016 $2,367 7,200,486 $0.00033 March 22, 2016 $5,315 11,682,000 $0.00046 March 28, 2016 $1,986 8,958,779 $0.00022 March 31, 2016 Total $602,376 194,603,040 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2016 $2,197 9,766,311 $0.000225 April 4, 2016 $4,847 17,250,000 $0.000281 April 7, 2016 $1,750 9,722,222 $0.000180 April 14, 2016 $4,158 19,250,000 $0.000216 April 15, 2016 $1,318 9,766,222 $0.000135 April 26, 2016 $1,705 12,629,776 $0.000135 May 4, 2016 $2,067 9,718,025 $0.000213 May 31, 2016 $ 828 4,600,055 $0.000180 June 2, 2016 $9,120 30,000,000 $0.000304 June 2, 2016 $4,401 29,340,333 $0.000150 June 14, 2016 $5,847 29,235,900 $0.000200 June 17,2016 $5,691 28,456,150 $0.000200 June 29, 2016 $6,580 21,270,355 $0.000309 August 23, 2016 $2,567 22,129,741 $0.000116 August 29, 2016 $2,570 22,156,120 $0.000116 September 6, 2016 $2,547 21,952,672 $0.000116 September 20, 2016 $2,443 25,267,655 $0.000097 September 26, 2016 $2,946 25,393,448 $0.000116 September 28, 2016 $2,947 25,403,448 $0.000116 September 30, 2016 $3,949 51,066,724 $0.000077 October 7, 2016 $3,381 58,291,551 $0.000058 October 14, 2016 $3,380 58,275,689 $0.000058 October 21, 2016 $3,385 58,355,689 $0.000058 October 26, 2016 $3,382 58,316,551 $0.000058 October 31, 2016 $5,037 86,837,068 $0.000058 November 7 , 2016 $5,015 86,472,931 $0.000058 November 22, 2016 $5,513 95,060,172 $0.000058 November 29, 2016 $5,515 95,092,931 $0.000058 December 6, 2016 $4,058 69,959,310 $0.000058 December 31, 2016 Total $109,144 1,091,037,049	Date Debt/Interest Converted Common Stock Issued Price per Share September 22, 2014 $ 12,000 5,505 $ 2.18 October 1, 2014 $ 12,000 6,487 $ 1.85 October 8, 2014 $ 9,000 5,056 $ 1.78 October 16, 2014 $ 6,000 4,546 $ 1.32 October 29, 2014 $ 15,000 12,500 $ 1.20 November 3, 2014 $ 10,000 8,197 $ 1.22 November 7, 2014 $ 12,000 11,881 $ 1.01 November 19, 2014 $ 18,120 28,312 $ 0.64 December 8, 2014 $ 15,000 34,884 $ 0.43 December 15, 2014 $ 12,000 42,857 $ 0.28 December 26, 2014 $ 17,200 74,783 $ 0.23 February 11, 2015 $ 29,900 747,500 $ 0.04 February 12, 2015 $ 17,333 373,561 $ 0.046 February 13, 2015 $ 17,894 372,800 $ 0.048 February 15, 2015 $ 35,730 739,243 $ 0.048 February 17, 2015 $ 17,003 366,440 $ 0.046 February 23, 2015 $ 20,603 470,900 $ 0.044 February 23, 2015 $ 17,003 366,440 $ 0.046 February 24, 2015 $ 9,488 204,473 $ 0.046 February 26, 2015 $ 42,030 1,050,750 $ 0.040 February 27, 2015 $ 26,880 560,000 $ 0.048 March 2, 2015 $ 56,402 1,215,551 $ 0.046 March 9, 2015 $ 33,900 475,182 $ 0.071 March 10, 2015 $ 25,200 700,000 $ 0.036 March 20, 2015 $ 10,000 181,818 $ 0.006 March 31, 2015 Total $ 498,686 8,059,666 Date Debt/Interest Converted Common Stock Issued Price per Share April 1, 2015 $ 16,650 411,111 $ 0.04050 April 6, 2015 $ 10,000 209,644 $ 0.04770 April 8, 2015 $ 15,309 453,561 $ 0.03375 April 8, 2015 $ 20,001 454,545 $ 0.04400 April 9, 2015 $ 14,320 325,455 $ 0.04400 April 14, 2015 $ 10,000 236,967 $ 0.04220 April 16, 2015 $ 1,918 53,000 $ 0.03619 April 21, 2015 $ 10,000 259,740 $ 0.03850 April 29, 2015 $ 15,000 389,610 $ 0.03850 May 4, 2015 $ 5,083 131,464 $ 0.03866 May 12, 2015 $ 28,456 903,380 $ 0.03150 May 20, 2015 $ 20,199 947,645 $ 0.02131 May 20, 015 $ 17,240 783,636 $ 0.02200 May 27, 2015 $ 13,568 701,801 $ 0.01933 May 29, 2015 $ 15,000 882,353 $ 0.01700 June 11, 2015 $ 9,897 942,609 $ 0.01050 June 16, 2015 $ 14,100 1,175,000 $ 0.01200 June 16, 2015 $ 13,565 1,130,417 $ 0.01200 June 22, 2015 $ 7,415 1,235,833 $ 0.00600 June 22, 2015 $ 14,384 2,479,924 $ 0.00580 June 23, 2015 $ 7,752 1,292,000 $ 0.00600 September 16, 2015 $ 7,974 1,772,033 $ 0.00450 September 28, 2015 $ 10,000 1,666,667 $ 0.00600 September 29, 2015 $ 10,620 1,770,000 $ 0.00600 October 7, 2015 $ 2,250 375,000 $ 0.00600 October 7, 2015 $ 8,400 1,400,000 $ 0.00600 October 19, 2015 $ 9,720 1,620,000 $ 0.00600 November 2, 2015 $ 4,424 1,966,124 $ 0.00225 November 23, 2015 $ 10,000 1,666,667 $ 0.00600 November 30, 2015 $ 16,844 2,591,323 $ 0.00650 December 9, 2015 $ 1,746 775,991 $ 0.00225 December 17, 2015 $ 5,332 919,319 $ 0.00580 December 28, 2015 $ 1,341 596,200 $ 0.00225 December 28, 2015 $ 17,700 2,950,000 $ 0.00600 December 28, 2015 $ 14,305 2,384,167 $ 0.00600 December 28, 2015 $ 14,963 2,579,916 $ 0.00580 December 29, 2015 $ 8,395 1,399,167 $ 0.00600 December 29, 2015 $ 7,670 1,278,333 $ 0.00600 December 30, 2015 $ 6,651 2,956,248 $ 0.00225 January 1, 2016 $ 28,500 4,384,615 $ 0.00650 January 4, 2016 $ 19,339 3,223,213 $ 0.00600 January 5, 2016 $ 8,107 3,603,227 $ 0.00225 January 6, 2016 $ 16,070 2,678,333 $ 0.00600 January 6, 2016 $ 16,597 2,861,607 $ 0.00580 February 16 ,2016 $ 1,424 4,220,400 $ 0.00034 February 17, 2016 $ 12,800 8,443,272 $ 0.00152 February 23, 2016 $ 4,640 4,218,182 $ 0.00110 February 23, 2016 $ 3,086 4,200,871 $ 0.00073 February 24, 2016 $ 1,492 4,419,970 $ 0.00034 February 25, 2016 $ 3,000 2,638,987 $ 0.00114 February 25, 2016 $ 4,640 4,218,182 $ 0.00110 March 1, 2016 $ 1,313 5,834,458 $ 0.00022 March 2, 2016 $ 4,600 5,831,643 $ 0.00079 March 2, 2016 $ 1,650 2,586,410 $ 0.00064 March 2, 2016 $ 9,332 11,650,000 $ 0.00080 March 7, 2016 $ 2,799 6,546,292 $ 0.00043 March 11, 2016 $ 1,924 4,147,500 $ 0.00046 March 14, 2016 $ 2,245 7,125,777 $ 0.00032 March 15, 2016 $ 3,329 7,454,098 $ 0.00045 March 15, 2016 $ 5,210 11,450,000 $ 0.00046 March 22, 2016 $ 2,419 8,957,888 $ 0.00027 March 22, 2016 $ 2,367 7,200,486 $ 0.00033 March 22, 2016 $ 5,315 11,682,000 $ 0.00046 March 28, 2016 $ 1,986 8,958,779 $ 0.00022 March 31, 2016 Total $ 602,376 194,603,040
Schedule of Value of Options	Date April 6, 2015 June 9, 2015 December 15, 2015 Options 2,040,003 1,000,000 860,000 Stock price grant date $0.08 $0.02 $0.01 Initial Exercise price $0.08 $0.02 $0.01 Modified Exercise price $0.01 $0.01 $0.01 Expected life 5.0 5.0 5.0 Volatility 99% 99% 84% Risk-free rate 1.31% 1.74% 1.70% Calculated value $120,778 $14,838 $5,736 Modified value $151,221 $16,347 $5,736	Date May 7, 2014 July 23, 2014 October 6, 2014 April 6, 2015 June 9, 2015 December 15, 2015 Options 35,000 7,500 155,000 2,040,003 1,000,000 860,000 Stock price grant date $12.00 $6.90 $3.58 $0.08 $0.02 $0.01 Initial Exercise price $12.00 $6.90 $1.91984 $0.08 $0.02 $0.01 Modified Exercise price $0.01 $0.01 $0.01 $0.01 $0.01 $0.01 Expected life 10.00 10.00 5.0 5.0 5.0 5.0 Volatility 73% 88% 101% 99% 99% 84% Risk-free rate 2.56% 2.53% 1.04% 1.31% 1.74% 1.70% Calculated value $315,772 $45,109 $454,798 $120,778 $14,838 $5,736 Modified value $7,164 $1,537 $31,408 $151,221 $16,347 $5,736
Schedule of Option Activity	Number of options Weighted average exercise price Outstanding, March 31, 2015 672,533 $0.01 Granted 3,900,003 $0.01 Exercised - - Expired - - Outstanding, December 31, 2016 4,572,536 $0.01	Number of options Weighted average exercise price Outstanding, March 31, 2014 475,033 $0.01 Granted 197,500 $0.01 Exercised - - Expired - - Outstanding, March 31, 2015 672,533 $0.01 Granted 3,900,003 $0.01 Exercised - - Expired - - Outstanding, March 31, 2016 4,572,536 $0.01

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Federal Income Tax	March 31, 2016 March 31, 2015 Federal income tax benefit attributable to: Current operations $ 601,276 $ 1,405,416 Less: valuation allowance (601,276 ) (1,405,416 ) Net provision for Federal income taxes $ — $ —
Schedule of Deferred Tax Asset	March 31, 2016 March 31, 2015 Deferred tax asset attributable to: Net operating loss carryover $ 3,129,170 $ 2,454,951 Less: valuation allowance (3,129,170 ) (2,454,951 ) Net deferred tax asset $ — $ —

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014shares	Sep. 30, 2013	Mar. 31, 2013	May 23, 2016shares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation		Aug. 9, 2010	Aug. 9, 2010
Common Stock, shares issued				14,690
Cancellation of loans | $				$ 6,009
Common Stock, Shares Authorized	4,000,000,000	4,000,000,000	4,000,000,000	4,000,000,000				4,000,000,000	375,030,000	900,000
Common Stock, Par Value | $ / shares	$ 0.001	$ 0.001	$ 0.001	$ .001					$ 0.001	$ 0.001
Stock split ratio		0.01	4.167			4.167	4.1671
Cash and cash equivalent | $				$ 15,892
Intangible assets | $	$ 0	0	0
Impairment of intangible asset | $		$ 82,120	$ 82,120
Reserved common shares	3,900,048	3,900,048	3,900,048
Stock options granted	197,500	3,900,003	197,500	197,500
Computer equipment		3 years	3 years
Options granted, number of shares	3,900,003		3,900,003	197,500	475,033
Options, exercise price | $ / shares		$ 0.001	$ 0.001
Sale Agmt
Date of Agreement		Jul. 19, 2013	Jul. 19, 2013
Cancellation of loans | $		$ 28,818	$ 28,818
Shares sold by former officers		5,312,925	5,312,925
Shares returned to treasury		5,002,554	5,002,554
Shares agreed to cancel		2,625,210	2,625,210
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013	Jul. 18, 2013
Common Stock, shares issued		827,670	827,670
Series A Preferred Stock, shares issued		6,000,000	6,000,000
Stock Value | $		$ 123,973	$ 123,973
Termination of agreement | $		20,000	20,000
Additional cash required | $		$ 2,000,000	$ 2,000,000

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Narrative) 9M	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014shares	Sep. 30, 2013	Mar. 31, 2013	May 23, 2016shares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares
Date Of Incorporation		Aug. 9, 2010	Aug. 9, 2010
Common Stock, shares issued				14,690
Cancellation of loans | $				$ 6,009
Common Stock, Shares Authorized	4,000,000,000	4,000,000,000	4,000,000,000	4,000,000,000				4,000,000,000	375,030,000	900,000
Common Stock, Par Value | $ / shares	$ 0.001	$ 0.001	$ 0.001	$ .001					$ 0.001	$ 0.001
Stock split ratio		0.01	4.167			4.167	4.1671
Cash and cash equivalent | $				$ 15,892
Intangible assets | $	$ 0	0	0
Impairment of intangible asset | $		$ 82,120	$ 82,120
Reserved common shares	3,900,048	3,900,048	3,900,048
Stock options granted	197,500	3,900,003	197,500	197,500
Computer equipment		3 years	3 years
Options granted, number of shares	3,900,003		3,900,003	197,500	475,033
Options, exercise price | $ / shares		$ 0.001	$ 0.001
Sale Agmt
Date of Agreement		Jul. 19, 2013	Jul. 19, 2013
Cancellation of loans | $		$ 28,818	$ 28,818
Shares sold by former officers		5,312,925	5,312,925
Shares returned to treasury		5,002,554	5,002,554
Shares agreed to cancel		2,625,210	2,625,210
Asset Assign Agmt
Date of Agreement		Jul. 18, 2013	Jul. 18, 2013
Common Stock, shares issued		827,670	827,670
Series A Preferred Stock, shares issued		6,000,000	6,000,000
Stock Value | $		$ 123,973	$ 123,973
Termination of agreement | $		20,000	20,000
Additional cash required | $		$ 2,000,000	$ 2,000,000

Property and equipment - Schedu

Property and equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Computer equipment	$ 5,160	$ 5,160	$ 1,419
Less: accumulated depreciation	(2,723)	(1,429)	(631)
Property and equipment, net	$ 2,437	$ 3,731	$ 788

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Property And Equipment Details Narrative
Depreciation expense	$ 431	$ 206	$ 1,293	$ 443	$ 799	$ 473
Computer equipment			3 years		3 years

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Common Stock, shares issued			14,690
Impairment of intangible asset	$ 82,120	$ 82,120
Asset Assign Agmt
Date of Agreement	Jul. 18, 2013	Jul. 18, 2013
Common Stock, shares issued	827,670	827,670
Series A Preferred Stock, shares issued	6,000,000	6,000,000
Stock Value	$ 123,973	$ 123,973
Asset Assign Agmt #2
Date of Agreement	Oct. 6, 2014	Oct. 6, 2014
Common Stock, shares issued	2,207,920	2,207,920
Common stock, value	$ 7,904,355	$ 7,904,355
Impaired Assets	0	0
Impairment of intangible asset	$ 82,120	$ 82,120

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2016	Mar. 31, 2016	Mar. 31, 2015
Payables and Accruals [Abstract]
Wages and taxes	$ 799,711	$ 514,713	$ 175,357
Accrued interest	96,903	15,437	25,534
Total accrued expenses	$ 896,614	$ 530,150	$ 200,891

Related Party Debt and Transa35

Related Party Debt and Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Cancellation of loans						$ 6,009
Due to related parties	$ 49,593		49,593		76,913	6,067
Loans and interest received (repaid) from/to related parties			(27,319)	$ 64,011	70,846
Interest expense, related party	$ (155)	$ (2)	$ (385)	$ (226)	$ (300)	(67)
Sale Agmt
Date of Agreement			Jul. 19, 2013		Jul. 19, 2013
Cancellation of loans			$ 28,818		$ 28,818
CEO
Loan from related party						5,000	$ 36,000
Repayment of loans to related parties						41,000
Shareholder
Loan from related party					$ 6,000
Interest Rate					8.00%
Interest expense, related party					$ (367)
Employment Agmt
Date of Agreement			Sep. 6, 2013		Sep. 6, 2013
Term of Agreement			2 years		2 years
Annual Compensation			$ 275,000		$ 275,000
Options to purchase			30,002		30,002
Options to purchase, exercise price			$ 0.02		$ 0.02
Bonus			$ 68,750		$ 68,750
Earnings			206,250		275,000	275,000
Accrued Earnings			$ 600,112		$ 395,630	$ 154,062

Related Party Debt and Transa36

Related Party Debt and Transactions (Details Narrative) 9M - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Cancellation of loans						$ 6,009
Due to related parties	$ 49,593		49,593		76,913	6,067
Loans and interest received (repaid) from/to related parties			(27,319)	$ 64,011	70,846
Interest expense, related party	(155)	$ (2)	(385)	$ (226)	(300)	(67)
Accrued expenses	$ 896,614		$ 896,614		$ 530,150	200,891
Sale Agmt
Date of Agreement			Jul. 19, 2013		Jul. 19, 2013
Cancellation of loans			$ 28,818		$ 28,818
CEO
Loan from related party						5,000	$ 36,000
Repayment of loans to related parties						41,000
SH Loan #1
Loan from related party						$ 6,000
Interest Rate						8.00%
SH Loan #2
Loan from related party			$ 6,280
Interest Rate	8.00%		8.00%
Interest expense, related party			$ (597)
Related Party Loans
Repayment of loans to related parties			36,300
Accrued expenses	$ 20,730		20,730		$ 28,200
Accrued expenses, balance due
Employment Agmt
Date of Agreement			Sep. 6, 2013		Sep. 6, 2013
Term of Agreement			2 years		2 years
Annual Compensation			$ 275,000		$ 275,000
Options to purchase			30,002		30,002
Options to purchase, exercise price			$ 0.02		$ 0.02
Bonus			$ 68,750		$ 68,750
Earnings			206,250		275,000	$ 275,000
Accrued Earnings			$ 600,112		$ 395,630	$ 154,062

Stock Deposits (Details Narrati

Stock Deposits (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Notes to Financial Statements
Stock deposits reclassified as common stock and stock warrants		$ 147,050	$ 147,050
Stock issued in exchange for deposits			14,690

Note Payable (Details Narrative

Note Payable (Details Narrative) 9M - Note Payable #1	9 Months Ended
	Dec. 31, 2016USD ($)
Date of Agreement	Aug. 13, 2014
Convertible Note	$ 900,000
Interest Rate	10.00%
Due Date	Aug. 1, 2017
Interest Accrued	$ 52,767

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument, Converted Amount		$ 109,144	$ 454,077	$ 602,374	$ 499,686
Debt Instrument, Interest Accrued, Converted Amount		9,584
Common Stock, shares issued					14,690
Convertible Prom Note #1
Date of Agreement					Mar. 11, 2014
Convertible Note					$ 37,500
Interest Rate					8.00%
Due Date					Dec. 13, 2014
Interest Accrued					$ 0
Convertible Note, Balance					0
Debt Instrument, Converted Amount					37,500
Debt Instrument, Interest Accrued, Converted Amount					$ 1,500
Common Stock, shares issued					21,593
Convertible Prom Note #2
Date of Agreement					Apr. 8, 2014
Convertible Note					$ 53,000
Interest Rate					8.00%
Due Date					Jan. 14, 2015
Interest Accrued					$ 0
Convertible Note, Balance					0
Debt Instrument, Converted Amount					53,000
Debt Instrument, Interest Accrued, Converted Amount					$ 2,120
Common Stock, shares issued					60,890
Convertible Prom Note #3
Date of Agreement					May 21, 2014
Convertible Note					$ 42,500
Interest Rate					8.00%
Due Date					Feb. 23, 2015
Interest Accrued					$ 0
Convertible Note, Balance					0
Debt Instrument, Converted Amount					42,500
Debt Instrument, Interest Accrued, Converted Amount					$ 1,700
Common Stock, shares issued					152,524
Convertible Prom Note #4
Date of Agreement					Aug. 14, 2014
Convertible Note					$ 66,780
Interest Rate					8.00%
Due Date					Aug. 14, 2015
Interest Accrued					$ 0
Convertible Note, Balance					0
Original Issue Discount					3,380
Debt Instrument, Converted Amount					66,780
Debt Instrument, Interest Accrued, Converted Amount					$ 2,850
Common Stock, shares issued					1,214,425
Convertible Prom Note #5
Date of Agreement					Aug. 14, 2014
Convertible Note					$ 58,300
Interest Rate					8.00%
Due Date					Aug. 14, 2015
Interest Accrued					$ 0
Convertible Note, Balance					0
Original Issue Discount					3,300
Debt Instrument, Converted Amount					58,300
Debt Instrument, Interest Accrued, Converted Amount					$ 2,527
Common Stock, shares issued					1,310,912
Convertible Prom Note #6
Date of Agreement					Aug. 13, 2014
Convertible Note					$ 61,111
Interest Rate					12.00%
Due Date					Aug. 14, 2016
Interest Accrued		0		0	$ 1,067
Convertible Note, Balance					0
Original Issue Discount					5,500
Debt Instrument, Converted Amount					61,111
Debt Instrument, Interest Accrued, Converted Amount		$ 1,067		$ 1,067	$ 6,266
Common Stock, shares issued		177,836		177,836	1,403,700
Convertible Prom Note #7
Date of Agreement				Aug. 19, 2014
Convertible Note				$ 57,895
Interest Rate				12.00%
Due Date				Aug. 19, 2016
Interest Accrued				$ 0
Convertible Note, Balance				0
Original Issue Discount				2,895
Debt Instrument, Converted Amount				57,895
Debt Instrument, Interest Accrued, Converted Amount				$ 14,035
Common Stock, shares issued				1,798,250
Convertible Prom Note #8
Date of Agreement					Sep. 18, 2014
Convertible Note					$ 64,500
Interest Rate					12.00%
Due Date					Sep. 18, 2015
Interest Accrued		$ 0		$ 0	$ 8,240
Convertible Note, Balance		0		0	54,500
Original Issue Discount					5,500
Debt Instrument, Converted Amount		54,500		54,500	$ 10,000
Debt Instrument, Interest Accrued, Converted Amount		$ 8,240		$ 8,240
Common Stock, shares issued		1,879,597		1,879,597	181,819
Convertible Prom Note #9
Date of Agreement					Sep. 23, 2014
Convertible Note					$ 55,000
Interest Rate					8.00%
Due Date					Jun. 23, 2015
Interest Accrued		$ 0		$ 0	$ 2,158
Convertible Note, Balance		0		0	29,800
Debt Instrument, Converted Amount		29,800		29,800	$ 25,200
Debt Instrument, Interest Accrued, Converted Amount		$ 2,158		$ 2,158
Common Stock, shares issued		864,672		864,672	700,000
Convertible Prom Note #10
Date of Agreement		Oct. 6, 2014		Oct. 6, 2014
Convertible Note		$ 33,000		$ 33,000
Interest Rate		8.00%		8.00%
Due Date		Jul. 6, 2015		Jul. 6, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		33,000		33,000
Debt Instrument, Interest Accrued, Converted Amount		$ 1,320		$ 1,320
Common Stock, shares issued		780,000		780,000
Convertible Prom Note #11
Date of Agreement		Nov. 6, 2014		Nov. 6, 2014
Convertible Note		$ 55,000		$ 55,000
Interest Rate		12.00%		12.00%
Due Date		May 6, 2015		May 6, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		55,000		55,000
Debt Instrument, Interest Accrued, Converted Amount		$ 3,553		$ 3,553
Common Stock, shares issued		2,813,634		2,813,634
Convertible Prom Note #12
Date of Agreement		Nov. 25, 2014		Nov. 25, 2014
Convertible Note		$ 43,000		$ 43,000
Interest Rate		8.00%		8.00%
Due Date		Aug. 28, 2015		Aug. 28, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		$ 46,510		$ 46,510
Common Stock, shares issued		5,290,270		5,290,270
Fee		Default		Default
Fee Amount				$ 3,510
Convertible Prom Note #13
Date of Agreement		Dec. 16, 2014		Dec. 16, 2014
Convertible Note		$ 33,333		$ 33,333
Interest Rate		12.00%		12.00%
Due Date		Dec. 16, 2016		Dec. 16, 2016
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Original Issue Discount		3,333		3,333
Debt Instrument, Converted Amount		33,333		33,333
Debt Instrument, Interest Accrued, Converted Amount		$ 4,000		$ 4,000
Common Stock, shares issued		5,047,167		5,047,167
Convertible Prom Note #14
Date of Agreement		Jan. 9, 2015		Jan. 9, 2015
Convertible Note		$ 33,000		$ 33,000
Interest Rate		8.00%		8.00%
Due Date		Oct. 13, 2015		Oct. 13, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Interest Accrued, Converted Amount		$ 1,320		$ 1,320
Common Stock, shares issued		8,470,000		8,470,000
Fee		Default		Default
Fee Amount				$ 16,500
Convertible Prom Note #15
Date of Agreement		Feb. 5, 2015		Feb. 5, 2015
Convertible Note		$ 54,000		$ 54,000
Interest Rate		8.00%		8.00%
Due Date		Nov. 9, 2015		Nov. 9, 2015
Interest Accrued		$ 11,819		$ 4,738
Convertible Note, Balance		$ 47,980		$ 47,980
Common Stock, shares issued		12,393,030		12,393,030
Fee		Default		Default
Fee Amount				$ 27,000
Convertible Prom Note #16
Date of Agreement		Feb. 17, 2015		Feb. 17, 2015
Convertible Note		$ 66,780		$ 66,780
Interest Rate		8.00%		8.00%
Due Date		Aug. 14, 2015		Aug. 14, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Original Issue Discount		6,780		6,780
Debt Instrument, Converted Amount		66,780		66,780
Debt Instrument, Interest Accrued, Converted Amount		$ 3,148		$ 3,148
Common Stock, shares issued		8,854,031		8,854,031
Convertible Prom Note #17
Date of Agreement		Feb. 25, 2015		Feb. 25, 2015
Convertible Note		$ 27,778		$ 27,778
Interest Rate		12.00%		12.00%
Due Date		Feb. 25, 2017		Feb. 25, 2017
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		27,778		27,778
Debt Instrument, Interest Accrued, Converted Amount		$ 3,333		$ 3,333
Common Stock, shares issued		5,185,210		5,185,210
Convertible Prom Note #18
Date of Agreement				Mar. 9, 2015
Convertible Note				$ 55,000
Interest Rate				8.00%
Due Date	Jun. 23, 2017			Dec. 9, 2015
Interest Accrued	$ 0	$ 357		$ 0
Convertible Note, Balance	8,838			16,215
Debt Instrument, Converted Amount	7,377			38,785
Debt Instrument, Interest Accrued, Converted Amount	$ 422			$ 5,135
Common Stock, shares issued	46,484,586			57,733,852
Convertible Prom Note #19
Date of Agreement				Mar. 26, 2015
Convertible Note				$ 29,680
Interest Rate				8.00%
Due Date				Mar. 23, 2016
Interest Accrued		5,496		$ 2,577
Convertible Note, Balance				18,751
Original Issue Discount				1,680
Debt Instrument, Converted Amount				$ 10,929
Common Stock, shares issued				15,924,728
Convertible Prom Note #20
Date of Agreement					Mar. 2, 2015
Convertible Note					$ 58,300
Interest Rate					8.00%
Due Date					Aug. 14, 2015
Interest Accrued		0		$ 0
Convertible Note, Balance		0		0	$ 1,898
Original Issue Discount					3,300
Debt Instrument, Converted Amount		1,898		1,898	$ 56,402
Debt Instrument, Interest Accrued, Converted Amount		$ 20		$ 20
Common Stock, shares issued		53,000		53,000	1,215,551
Convertible Prom Note #21
Date of Agreement				May 5, 2015
Convertible Note				$ 68,900
Interest Rate				8.00%
Due Date				May 5, 2016
Interest Accrued		$ 0		$ 4,387
Convertible Note, Balance		0		60,439
Original Issue Discount				3,900
Original Issue Discount, unamortized				325
Debt Instrument, Converted Amount		60,439		8,461
Debt Instrument, Interest Accrued, Converted Amount		$ 6,839		$ 566
Common Stock, shares issued		891,020,080		18,135,267
Convertible Prom Note #22
Date of Agreement				May 6, 2015
Convertible Note				$ 10,500
Interest Rate				8.00%
Due Date				Feb. 8, 2016
Interest Accrued		$ 5,150		$ 1,133
Convertible Note, Balance				$ 15,750
Fee				Default
Fee Amount		$ 5,250		$ 5,250
Convertible Prom Note #23
Date of Agreement		May 27, 2015		May 27, 2015
Convertible Note		$ 16,500		$ 16,500
Interest Rate		8.00%		8.00%
Due Date		May 28, 2016		May 28, 2016
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		16,500		16,500
Debt Instrument, Interest Accrued, Converted Amount		$ 344		$ 344
Common Stock, shares issued		2,591,323		2,591,323
Convertible Prom Note #24
Date of Agreement		Aug. 28, 2015		Aug. 28, 2015
Convertible Note		$ 15,000		$ 15,000
Interest Rate		8.00%		8.00%
Due Date		Aug. 28, 2016		Aug. 28, 2016
Interest Accrued		$ 0		$ 710
Convertible Note, Balance		0		$ 15,000
Debt Instrument, Converted Amount		15,000
Debt Instrument, Interest Accrued, Converted Amount		$ 939
Common Stock, shares issued		87,032,383
Convertible Prom Note #25
Date of Agreement		Sep. 4, 2015		Sep. 4, 2015
Convertible Note		$ 19,000		$ 19,000
Interest Rate		8.00%		8.00%
Due Date		Jun. 4, 2016		Jun. 4, 2016
Interest Accrued		$ 2,016		$ 870
Convertible Note, Balance		$ 19,000		$ 19,000
Convertible Prom Note #26
Date of Agreement				Dec. 29, 2015
Convertible Note				$ 57,378
Interest Rate				8.00%
Due Date		Jun. 23, 2017		Dec. 30, 2016
Interest Accrued		$ 83		$ 0
Convertible Note, Balance				1,609
Debt Instrument, Converted Amount				59,934
Debt Instrument, Interest Accrued, Converted Amount				$ 1,222
Common Stock, shares issued				35,927,887
Fee				Default
Fee Amount				$ 4,165
Convertible Prom Note #27
Date of Agreement		Jan. 22, 2016		Jan. 22, 2016
Convertible Note		$ 60,500		$ 60,500
Interest Rate		10.00%		10.00%
Due Date		Oct. 22, 2016		Oct. 22, 2016
Interest Accrued		$ 5,702		$ 1,144
Convertible Prom Note #28
Date of Agreement		Feb. 25, 2016		Feb. 25, 2016
Convertible Note		$ 27,500		$ 27,500
Interest Rate		8.00%		8.00%
Due Date		Feb. 25, 2017		Feb. 25, 2017
Interest Accrued		$ 434		$ 191
Convertible Note, Balance		10,755		27,500
Original Issue Discount, unamortized		212		2,084
Debt Instrument, Converted Amount		16,745		$ 5,315
Debt Instrument, Interest Accrued, Converted Amount		$ 1,380
Common Stock, shares issued		66,500,000		11,682,000
Convertible Prom Note #29
Date of Agreement		Mar. 24, 2016		Mar. 24, 2016
Convertible Note		$ 7,500		$ 7,500
Interest Rate		8.00%		8.00%
Due Date		Mar. 24, 2017		Mar. 24, 2017
Interest Accrued		$ 464		$ 2

Convertible Note Payable (Det40

Convertible Note Payable (Details Narrative) 9M - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument, Converted Amount		$ 109,144	$ 454,077	$ 602,374	$ 499,686
Debt Instrument, Interest Accrued, Converted Amount		9,584
Common Stock, shares issued					14,690
Convertible Prom Note #6
Date of Agreement					Aug. 13, 2014
Convertible Note					$ 61,111
Interest Rate					12.00%
Due Date					Aug. 14, 2016
Interest Accrued		0		0	$ 1,067
Convertible Note, Balance					0
Original Issue Discount					5,500
Debt Instrument, Converted Amount					61,111
Debt Instrument, Interest Accrued, Converted Amount		$ 1,067		$ 1,067	$ 6,266
Common Stock, shares issued		177,836		177,836	1,403,700
Convertible Prom Note #8
Date of Agreement					Sep. 18, 2014
Convertible Note					$ 64,500
Interest Rate					12.00%
Due Date					Sep. 18, 2015
Interest Accrued		$ 0		$ 0	$ 8,240
Convertible Note, Balance		0		0	54,500
Original Issue Discount					5,500
Debt Instrument, Converted Amount		54,500		54,500	$ 10,000
Debt Instrument, Interest Accrued, Converted Amount		$ 8,240		$ 8,240
Common Stock, shares issued		1,879,597		1,879,597	181,819
Convertible Prom Note #9
Date of Agreement					Sep. 23, 2014
Convertible Note					$ 55,000
Interest Rate					8.00%
Due Date					Jun. 23, 2015
Interest Accrued		$ 0		$ 0	$ 2,158
Convertible Note, Balance		0		0	29,800
Debt Instrument, Converted Amount		29,800		29,800	$ 25,200
Debt Instrument, Interest Accrued, Converted Amount		$ 2,158		$ 2,158
Common Stock, shares issued		864,672		864,672	700,000
Convertible Prom Note #10
Date of Agreement		Oct. 6, 2014		Oct. 6, 2014
Convertible Note		$ 33,000		$ 33,000
Interest Rate		8.00%		8.00%
Due Date		Jul. 6, 2015		Jul. 6, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		33,000		33,000
Debt Instrument, Interest Accrued, Converted Amount		$ 1,320		$ 1,320
Common Stock, shares issued		780,000		780,000
Convertible Prom Note #11
Date of Agreement		Nov. 6, 2014		Nov. 6, 2014
Convertible Note		$ 55,000		$ 55,000
Interest Rate		12.00%		12.00%
Due Date		May 6, 2015		May 6, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		55,000		55,000
Debt Instrument, Interest Accrued, Converted Amount		$ 3,553		$ 3,553
Common Stock, shares issued		2,813,634		2,813,634
Convertible Prom Note #12
Date of Agreement		Nov. 25, 2014		Nov. 25, 2014
Convertible Note		$ 43,000		$ 43,000
Interest Rate		8.00%		8.00%
Due Date		Aug. 28, 2015		Aug. 28, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		$ 46,510		$ 46,510
Common Stock, shares issued		5,290,270		5,290,270
Fee		Default		Default
Fee Amount				$ 3,510
Convertible Prom Note #13
Date of Agreement		Dec. 16, 2014		Dec. 16, 2014
Convertible Note		$ 33,333		$ 33,333
Interest Rate		12.00%		12.00%
Due Date		Dec. 16, 2016		Dec. 16, 2016
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Original Issue Discount		3,333		3,333
Debt Instrument, Converted Amount		33,333		33,333
Debt Instrument, Interest Accrued, Converted Amount		$ 4,000		$ 4,000
Common Stock, shares issued		5,047,167		5,047,167
Convertible Prom Note #14
Date of Agreement		Jan. 9, 2015		Jan. 9, 2015
Convertible Note		$ 33,000		$ 33,000
Interest Rate		8.00%		8.00%
Due Date		Oct. 13, 2015		Oct. 13, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Interest Accrued, Converted Amount		$ 1,320		$ 1,320
Common Stock, shares issued		8,470,000		8,470,000
Fee		Default		Default
Fee Amount				$ 16,500
Convertible Prom Note #15
Date of Agreement		Feb. 5, 2015		Feb. 5, 2015
Convertible Note		$ 54,000		$ 54,000
Interest Rate		8.00%		8.00%
Due Date		Nov. 9, 2015		Nov. 9, 2015
Interest Accrued		$ 11,819		$ 4,738
Convertible Note, Balance		$ 47,980		$ 47,980
Common Stock, shares issued		12,393,030		12,393,030
Fee		Default		Default
Fee Amount				$ 27,000
Convertible Prom Note #16
Date of Agreement		Feb. 17, 2015		Feb. 17, 2015
Convertible Note		$ 66,780		$ 66,780
Interest Rate		8.00%		8.00%
Due Date		Aug. 14, 2015		Aug. 14, 2015
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Original Issue Discount		6,780		6,780
Debt Instrument, Converted Amount		66,780		66,780
Debt Instrument, Interest Accrued, Converted Amount		$ 3,148		$ 3,148
Common Stock, shares issued		8,854,031		8,854,031
Convertible Prom Note #17
Date of Agreement		Feb. 25, 2015		Feb. 25, 2015
Convertible Note		$ 27,778		$ 27,778
Interest Rate		12.00%		12.00%
Due Date		Feb. 25, 2017		Feb. 25, 2017
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		27,778		27,778
Debt Instrument, Interest Accrued, Converted Amount		$ 3,333		$ 3,333
Common Stock, shares issued		5,185,210		5,185,210
Convertible Prom Note #18
Date of Agreement				Mar. 9, 2015
Convertible Note				$ 55,000
Interest Rate				8.00%
Due Date	Jun. 23, 2017			Dec. 9, 2015
Interest Accrued	$ 0	$ 357		$ 0
Convertible Note, Balance	8,838			16,215
Debt Instrument, Converted Amount	7,377			38,785
Debt Instrument, Interest Accrued, Converted Amount	$ 422			$ 5,135
Common Stock, shares issued	46,484,586			57,733,852
Convertible Prom Note #19
Date of Agreement				Mar. 26, 2015
Convertible Note				$ 29,680
Interest Rate				8.00%
Due Date				Mar. 23, 2016
Interest Accrued		5,496		$ 2,577
Convertible Note, Balance				18,751
Original Issue Discount				1,680
Debt Instrument, Converted Amount				$ 10,929
Common Stock, shares issued				15,924,728
Convertible Prom Note #20
Date of Agreement					Mar. 2, 2015
Convertible Note					$ 58,300
Interest Rate					8.00%
Due Date					Aug. 14, 2015
Interest Accrued		0		$ 0
Convertible Note, Balance		0		0	$ 1,898
Original Issue Discount					3,300
Debt Instrument, Converted Amount		1,898		1,898	$ 56,402
Debt Instrument, Interest Accrued, Converted Amount		$ 20		$ 20
Common Stock, shares issued		53,000		53,000	1,215,551
Convertible Prom Note #21
Date of Agreement				May 5, 2015
Convertible Note				$ 68,900
Interest Rate				8.00%
Due Date				May 5, 2016
Interest Accrued		$ 0		$ 4,387
Convertible Note, Balance		0		60,439
Original Issue Discount				3,900
Original Issue Discount, unamortized				325
Debt Instrument, Converted Amount		60,439		8,461
Debt Instrument, Interest Accrued, Converted Amount		$ 6,839		$ 566
Common Stock, shares issued		891,020,080		18,135,267
Convertible Prom Note #22
Date of Agreement				May 6, 2015
Convertible Note				$ 10,500
Interest Rate				8.00%
Due Date				Feb. 8, 2016
Interest Accrued		$ 5,150		$ 1,133
Convertible Note, Balance				$ 15,750
Fee				Default
Fee Amount		$ 5,250		$ 5,250
Convertible Prom Note #23
Date of Agreement		May 27, 2015		May 27, 2015
Convertible Note		$ 16,500		$ 16,500
Interest Rate		8.00%		8.00%
Due Date		May 28, 2016		May 28, 2016
Interest Accrued		$ 0		$ 0
Convertible Note, Balance		0		0
Debt Instrument, Converted Amount		16,500		16,500
Debt Instrument, Interest Accrued, Converted Amount		$ 344		$ 344
Common Stock, shares issued		2,591,323		2,591,323
Convertible Prom Note #24
Date of Agreement		Aug. 28, 2015		Aug. 28, 2015
Convertible Note		$ 15,000		$ 15,000
Interest Rate		8.00%		8.00%
Due Date		Aug. 28, 2016		Aug. 28, 2016
Interest Accrued		$ 0		$ 710
Convertible Note, Balance		0		$ 15,000
Debt Instrument, Converted Amount		15,000
Debt Instrument, Interest Accrued, Converted Amount		$ 939
Common Stock, shares issued		87,032,383
Convertible Prom Note #25
Date of Agreement		Sep. 4, 2015		Sep. 4, 2015
Convertible Note		$ 19,000		$ 19,000
Interest Rate		8.00%		8.00%
Due Date		Jun. 4, 2016		Jun. 4, 2016
Interest Accrued		$ 2,016		$ 870
Convertible Note, Balance		$ 19,000		$ 19,000
Convertible Prom Note #26
Date of Agreement				Dec. 29, 2015
Convertible Note				$ 57,378
Interest Rate				8.00%
Due Date		Jun. 23, 2017		Dec. 30, 2016
Interest Accrued		$ 83		$ 0
Convertible Note, Balance				1,609
Debt Instrument, Converted Amount				59,934
Debt Instrument, Interest Accrued, Converted Amount				$ 1,222
Common Stock, shares issued				35,927,887
Fee				Default
Fee Amount				$ 4,165
Convertible Prom Note #27
Date of Agreement		Jan. 22, 2016		Jan. 22, 2016
Convertible Note		$ 60,500		$ 60,500
Interest Rate		10.00%		10.00%
Due Date		Oct. 22, 2016		Oct. 22, 2016
Interest Accrued		$ 5,702		$ 1,144
Convertible Prom Note #28
Date of Agreement		Feb. 25, 2016		Feb. 25, 2016
Convertible Note		$ 27,500		$ 27,500
Interest Rate		8.00%		8.00%
Due Date		Feb. 25, 2017		Feb. 25, 2017
Interest Accrued		$ 434		$ 191
Convertible Note, Balance		10,755		27,500
Original Issue Discount, unamortized		212		2,084
Debt Instrument, Converted Amount		16,745		$ 5,315
Debt Instrument, Interest Accrued, Converted Amount		$ 1,380
Common Stock, shares issued		66,500,000		11,682,000
Convertible Prom Note #29
Date of Agreement		Mar. 24, 2016		Mar. 24, 2016
Convertible Note		$ 7,500		$ 7,500
Interest Rate		8.00%		8.00%
Due Date		Mar. 24, 2017		Mar. 24, 2017
Interest Accrued		$ 464		$ 2
Convertible Prom Note #34
Date of Agreement		May 25, 2016
Convertible Note		$ 30,000
Interest Rate		8.00%
Due Date		May 25, 2017
Interest Accrued		$ 1,447
Convertible Prom Note #30
Date of Agreement		Jun. 8, 2016
Convertible Note		$ 84,250
Interest Rate		8.00%
Due Date		Jun. 8, 2017
Interest Accrued		$ 3,804
Convertible Prom Note #32
Date of Agreement		Jun. 23, 2016
Convertible Note		$ 56,000
Interest Rate		8.00%
Due Date		Jun. 23, 2017
Interest Accrued		$ 2,344
Convertible Prom Note #35
Date of Agreement		Jul. 7, 2016
Convertible Note		$ 58,000
Interest Rate		8.00%
Due Date		Jul. 7, 2017
Interest Accrued		$ 2,172
Convertible Prom Note #36
Date of Agreement		Oct. 20, 2016
Convertible Note		$ 32,000
Interest Rate		8.00%
Due Date		Oct. 20, 2017
Interest Accrued		$ 505
Convertible Prom Note #37
Date of Agreement		Nov. 17, 2016
Convertible Note		$ 56,000
Interest Rate		8.00%
Due Date		Jun. 23, 2017
Interest Accrued		$ 2,344

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Notes to Financial Statements
Change in value of derivative liability	$ 84,508	$ 399,810	$ (83,946)	$ 169,624	$ (563,432)	$ (1,867,621)
Derivative expense	(170,250)	$ (47,469)	(170,250)	$ (382,713)	497,213	1,809,914
Debt Discount, Unamortized	130,631		130,631		88,365
Derivative liabilities	618,060		618,060		446,912	139,983
Derivative liabilities						$ 77,775
Debt Discounts, Conversion Features	$ 105,366		$ 105,366

Equity Transactions - Schedule

Equity Transactions - Schedule of Value of Warrants (Details) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Fair value allocation of proceeds		$ 42,871
Warrant #1
Date	Oct. 29, 2013		Oct. 29, 2013
Warrants	$ 2,500		$ 2,500
Stock price on grant date	$ 30		$ 30
Exercise price	$ 50		$ 50
Expected life	1 year		1 year
Volatility			147.00%
Risk-free rate			0.12%
Calculated value			$ 10,473
Fair value allocation of proceeds			$ 7,381
Warrant #2
Date	Dec. 11, 2013		Dec. 11, 2013
Warrants	$ 2,500		$ 2,500
Stock price on grant date	$ 30		$ 2
Exercise price	$ 50		$ 50
Expected life	1 year		1 year
Volatility			64.00%
Risk-free rate			0.11%
Calculated value			$ 0
Fair value allocation of proceeds			$ 0
Warrant #3
Date	Jun. 9, 2015		Mar. 10, 2014
Warrants	$ 900,000		$ 833
Stock price on grant date			$ 2
Exercise price	$ 0.02		$ 50
Expected life	5 years		1 year
Volatility			65.00%
Risk-free rate			0.13%
Calculated value			$ 0
Fair value allocation of proceeds			$ 0
Warrant #4
Date	Dec. 15, 2016		Apr. 4, 2014
Warrants	$ 4,000,000		$ 833
Stock price on grant date			$ 19.90
Exercise price	$ 0.01		$ 50
Expected life	5 years		1 year
Volatility			113.00%
Risk-free rate			0.12%
Calculated value			$ 3,181
Fair value allocation of proceeds			$ 2,822
Warrant #5
Date			Apr. 24, 2014
Warrants			$ 10,000
Stock price on grant date			$ 25.20
Exercise price			$ 35
Expected life			3 years
Volatility			76.00%
Risk-free rate			0.84%
Calculated value			$ 104,416
Fair value allocation of proceeds			$ 73,653
Warrant #6
Date			Jul. 10, 2014
Warrants			$ 7,000
Stock price on grant date			$ 3.70
Exercise price			$ 15
Expected life			3 years
Volatility			119.00%
Risk-free rate			0.96%
Calculated value			$ 12,130
Fair value allocation of proceeds			$ 8,637
Warrant #7
Date			Jul. 29, 2014
Warrants			$ 7,000
Stock price on grant date			$ 3.70
Exercise price			$ 15
Expected life			3 years
Volatility			119.00%
Risk-free rate			0.98%
Calculated value			$ 12,102
Fair value allocation of proceeds			$ 8,992
Warrant #8
Date	Jun. 9, 2015		Jun. 9, 2015
Warrants	$ 900,000		$ 900,000
Stock price on grant date	$ 0.02		$ 0.02
Exercise price	$ 0.02		$ 0.02
Expected life	5 years		5 years
Volatility	98.00%		98.00%
Risk-free rate	1.74%		1.74%
Calculated value	$ 13,259		$ 13,259
Fair value allocation of proceeds	$ 13,259		$ 13,259
Warrant #9
Date	Dec. 15, 2015		Dec. 15, 2015
Warrants	$ 4,000,000		$ 4,000,000
Stock price on grant date	$ 0.01		$ 0.01
Exercise price	$ 0.01		$ 0.01
Expected life	5 years		5 years
Volatility	98.00%		98.00%
Risk-free rate	1.71%		1.71%
Calculated value	$ 29,612		$ 29,612
Fair value allocation of proceeds	$ 29,612		$ 29,612

Equity Transactions - Schedul43

Equity Transactions - Schedule of Value of Warrants (Details) 9M - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016
Fair value allocation of proceeds		$ 42,871
Warrant #8
Date	Jun. 9, 2015		Jun. 9, 2015
Warrants	$ 900,000		$ 900,000
Stock price on grant date	$ 0.02		$ 0.02
Exercise price	$ 0.02		$ 0.02
Expected life	5 years		5 years
Volatility	98.00%		98.00%
Risk-free rate	1.74%		1.74%
Calculated value	$ 13,259		$ 13,259
Fair value allocation of proceeds	$ 13,259		$ 13,259
Warrant #9
Date	Dec. 15, 2015		Dec. 15, 2015
Warrants	$ 4,000,000		$ 4,000,000
Stock price on grant date	$ 0.01		$ 0.01
Exercise price	$ 0.01		$ 0.01
Expected life	5 years		5 years
Volatility	98.00%		98.00%
Risk-free rate	1.71%		1.71%
Calculated value	$ 29,612		$ 29,612
Fair value allocation of proceeds	$ 29,612		$ 29,612

Equity Transactions - Schedul44

Equity Transactions - Schedule of Warrant Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	4,930,666	30,666	5,833
Beginning Balance, Average Exercise Price	$ 0.192	$ 29	$ 50
Issued, Warrants			24,833	5,833
Issued, Average Exercise Price			$ 50	$ 50
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants		4,930,666	30,666	5,833
Ending Balance, Average Exercise Price		$ 0.192	$ 29	$ 50

Equity Transactions - Schedul45

Equity Transactions - Schedule of Warrant Activity (Details) 9M - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, Issued Warrants	4,930,666	30,666	5,833
Beginning Balance, Average Exercise Price	$ 0.192	$ 29	$ 50
Issued, Warrants			24,833	5,833
Issued, Average Exercise Price			$ 50	$ 50
Exercised, Warrants
Exercised, Average Exercise Price
Expired Warrants
Expired Average Exercise Price
Ending Balance, Issued Warrants		4,930,666	30,666	5,833
Ending Balance, Average Exercise Price		$ 0.192	$ 29	$ 50

Equity Transactions - Schedul46

Equity Transactions - Schedule of Value of Options (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Stock Option 4
Date of Issuance		May 7, 2014
Options		35,000
Stock price on grant date		$ 12
Exercise price		12
Exercise price, modified		$ 0.01
Expected life		10 years
Volatility		73.00%
Risk-free rate		2.56%
Calculated value		$ 315,772
Modified value		$ 7,164
Stock Option 5
Date of Issuance		Jul. 23, 2014
Options		7,500
Stock price on grant date		$ 6.90
Exercise price		6.90
Exercise price, modified		$ 0.01
Expected life		10 years
Volatility		88.00%
Risk-free rate		2.53%
Calculated value		$ 45,109
Modified value		$ 1,537
Stock Option 6
Date of Issuance		Oct. 6, 2014
Options		155,000
Stock price on grant date		$ 3.58
Exercise price		1.91984
Exercise price, modified		$ 0.01
Expected life		5 years
Volatility		101.00%
Risk-free rate		1.04%
Calculated value		$ 454,798
Modified value		$ 31,408
Stock Option 7
Date of Issuance	Apr. 6, 2015	Apr. 6, 2015
Options	2,040,003	2,040,003
Stock price on grant date	$ 0.08	$ 0.08
Exercise price	0.08	0.08
Exercise price, modified	$ 0.01	$ 0.01
Expected life	5 years	5 years
Volatility	99.00%	99.00%
Risk-free rate	1.31%	1.31%
Calculated value	$ 120,778	$ 120,778
Modified value	$ 151,221	$ 151,221
Stock Option 8
Date of Issuance	Jun. 9, 2015	Jun. 9, 2015
Options	1,000,000	1,000,000
Stock price on grant date	$ 0.02	$ 0.02
Exercise price	0.02	0.02
Exercise price, modified	$ 0.01	$ 0.01
Expected life	5 years	5 years
Volatility	99.00%	99.00%
Risk-free rate	1.74%	1.74%
Calculated value	$ 14,838	$ 14,838
Modified value	$ 16,347	$ 16,347
Stock Option 9
Date of Issuance	Dec. 15, 2015	Dec. 15, 2015
Options	860,000	860,000
Stock price on grant date	$ 0.01	$ 0.01
Exercise price	0.01	0.01
Exercise price, modified	$ 0.01	$ 0.01
Expected life	5 years	5 years
Volatility	84.00%	84.00%
Risk-free rate	1.70%	1.70%
Calculated value	$ 5,736	$ 5,736
Modified value	$ 5,736	$ 5,736

Equity Transactions - Schedul47

Equity Transactions - Schedule of Value of Options (Details) 9M - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Stock Option 7
Date of Issuance	Apr. 6, 2015	Apr. 6, 2015
Options	2,040,003	2,040,003
Stock price on grant date	$ 0.08	$ 0.08
Exercise price	0.08	0.08
Exercise price, modified	$ 0.01	$ 0.01
Expected life	5 years	5 years
Volatility	99.00%	99.00%
Risk-free rate	1.31%	1.31%
Calculated value	$ 120,778	$ 120,778
Modified value	$ 151,221	$ 151,221
Stock Option 8
Date of Issuance	Jun. 9, 2015	Jun. 9, 2015
Options	1,000,000	1,000,000
Stock price on grant date	$ 0.02	$ 0.02
Exercise price	0.02	0.02
Exercise price, modified	$ 0.01	$ 0.01
Expected life	5 years	5 years
Volatility	99.00%	99.00%
Risk-free rate	1.74%	1.74%
Calculated value	$ 14,838	$ 14,838
Modified value	$ 16,347	$ 16,347
Stock Option 9
Date of Issuance	Dec. 15, 2015	Dec. 15, 2015
Options	860,000	860,000
Stock price on grant date	$ 0.01	$ 0.01
Exercise price	0.01	0.01
Exercise price, modified	$ 0.01	$ 0.01
Expected life	5 years	5 years
Volatility	84.00%	84.00%
Risk-free rate	1.70%	1.70%
Calculated value	$ 5,736	$ 5,736
Modified value	$ 5,736	$ 5,736

Equity Transactions - Schedul48

Equity Transactions - Schedule of Option Activity (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, number of shares		672,533	475,033
Beginning Balance, weighted average exercise price		0.01	0.01	0
Options granted, number of shares	3,900,003	3,900,003	197,500	475,033
Options granted, weighted average exercise price				0.01
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares	4,572,536	4,572,536	672,533	475,033
Ending Balance, weighted average exercise price	0.01	0.01	0.01	0.01

Equity Transactions - Schedul49

Equity Transactions - Schedule of Option Activity (Details) 9M - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Accounting Policies [Abstract]
Beginning Balance, number of shares		672,533	475,033
Beginning Balance, weighted average exercise price		0.01	0.01	0
Options granted, number of shares	3,900,003	3,900,003	197,500	475,033
Options granted, weighted average exercise price				0.01
Options exercised, number of shares
Options exercised, weighted average exercise price
Options expired, number of shares
Options expired, weighted average exercise price
Ending Balance, number of shares	4,572,536	4,572,536	672,533	475,033
Ending Balance, weighted average exercise price	0.01	0.01	0.01	0.01

Equity Transactions (Details Na

Equity Transactions (Details Narrative)	3 Months Ended	9 Months Ended		12 Months Ended
	Mar. 31, 2016$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014shares	Sep. 30, 2013	Mar. 31, 2013	May 23, 2016shares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares	Jul. 18, 2013shares
Common Stock, Shares Authorized	4,000,000,000	4,000,000,000		4,000,000,000	4,000,000,000				4,000,000,000	375,030,000	900,000
Common Stock, Par Value | $ / shares	$ 0.001	$ 0.001		$ 0.001	$ .001					$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000		10,000,000	10,000,000
Preferred Stock, Par Value | $ / shares	$ .001	$ 0.001		$ .001	$ .001
Series A Preferred Stock, Designated												6,000,000
Common Stock, Issued	216,364,262	1,307,401,310		216,364,262	15,410,840
Preferred Stock, Issued	6,000,000	6,000,000		6,000,000	6,000,000
Common Stock, shares issued					14,690
Stock split ratio		0.01		4.167			4.167	4.1671
Options granted, number of shares	3,900,003			3,900,003	197,500	475,033
Shares issued for services						1,182,141
Shares issued for services, value | $				$ 49,155	$ 796,050
Debt Instrument, Converted Amount | $		$ 109,144	$ 454,077	602,374	499,686
Stock-based compensation | $			$ 198,128	$ 240,999	$ 866,128
Debt Conversion #1
Date of Issuance				Sep. 22, 2014
Common Stock, shares issued				5,505
Common Stock, price per share | $ / shares				$ 2.18
Debt Instrument, Converted Amount | $				$ 12,000
Debt Conversion #2
Date of Issuance				Oct. 1, 2014
Common Stock, shares issued				6,487
Common Stock, price per share | $ / shares				$ 1.85
Debt Instrument, Converted Amount | $				$ 12,000
Debt Conversion #3
Date of Issuance				Oct. 8, 2014
Common Stock, shares issued				5,056
Common Stock, price per share | $ / shares				$ 1.78
Debt Instrument, Converted Amount | $				$ 9,000
Debt Conversion #4
Date of Issuance				Oct. 16, 2014
Common Stock, shares issued				4,546
Common Stock, price per share | $ / shares				$ 1.32
Debt Instrument, Converted Amount | $				$ 6,000
Debt Conversion #5
Date of Issuance				Oct. 29, 2014
Common Stock, shares issued				12,500
Common Stock, price per share | $ / shares				$ 1.20
Debt Instrument, Converted Amount | $				$ 15,000
Debt Conversion #6
Date of Issuance				Nov. 3, 2014
Common Stock, shares issued				8,197
Common Stock, price per share | $ / shares				$ 1.22
Debt Instrument, Converted Amount | $				$ 10,000
Debt Conversion #7
Date of Issuance				Nov. 7, 2014
Common Stock, shares issued				11,881
Common Stock, price per share | $ / shares				$ 1.01
Debt Instrument, Converted Amount | $				$ 12,000
Debt Conversion #8
Date of Issuance				Nov. 19, 2014
Common Stock, shares issued				28,312
Common Stock, price per share | $ / shares				$ 0.64
Debt Instrument, Converted Amount | $				$ 18,120
Debt Conversion #9
Date of Issuance				Dec. 8, 2014
Common Stock, shares issued				34,884
Common Stock, price per share | $ / shares				$ 0.43
Debt Instrument, Converted Amount | $				$ 15,000
Debt Conversion #10
Date of Issuance				Dec. 15, 2014
Common Stock, shares issued				42,857
Common Stock, price per share | $ / shares				$ 0.28
Debt Instrument, Converted Amount | $				$ 12,000
Debt Conversion #11
Date of Issuance				Dec. 26, 2014
Common Stock, shares issued				74,783
Common Stock, price per share | $ / shares				$ 0.23
Debt Instrument, Converted Amount | $				$ 17,200
Debt Conversion #12
Date of Issuance				Feb. 11, 2015
Common Stock, shares issued				747,500
Common Stock, price per share | $ / shares				$ 0.04
Debt Instrument, Converted Amount | $				$ 29,900
Debt Conversion #13
Date of Issuance				Feb. 12, 2015
Common Stock, shares issued				373,561
Common Stock, price per share | $ / shares				$ 0.046
Debt Instrument, Converted Amount | $				$ 17,333
Debt Conversion #15
Date of Issuance				Feb. 13, 2015
Common Stock, shares issued				372,800
Common Stock, price per share | $ / shares				$ 0.048
Debt Instrument, Converted Amount | $				$ 17,894
Debt Conversion #14
Date of Issuance				Feb. 15, 2015
Common Stock, shares issued				739,243
Common Stock, price per share | $ / shares				$ 0.048
Debt Instrument, Converted Amount | $				$ 35,730
Debt Conversion #16
Date of Issuance				Feb. 17, 2015
Common Stock, shares issued				366,440
Common Stock, price per share | $ / shares				$ 0.046
Debt Instrument, Converted Amount | $				$ 17,003
Debt Conversion #17
Date of Issuance				Feb. 23, 2015
Common Stock, shares issued				470,900
Common Stock, price per share | $ / shares				$ 0.044
Debt Instrument, Converted Amount | $				$ 20,603
Debt Conversion #18
Date of Issuance				Feb. 23, 2015
Common Stock, shares issued				366,440
Common Stock, price per share | $ / shares				$ 0.046
Debt Instrument, Converted Amount | $				$ 17,003
Debt Conversion #19
Date of Issuance				Feb. 24, 2015
Common Stock, shares issued				204,473
Common Stock, price per share | $ / shares				$ 0.046
Debt Instrument, Converted Amount | $				$ 9,488
Debt Conversion #20
Date of Issuance				Feb. 26, 2015
Common Stock, shares issued				1,050,750
Common Stock, price per share | $ / shares				$ 0.040
Debt Instrument, Converted Amount | $				$ 42,030
Debt Conversion #21
Date of Issuance				Feb. 27, 2015
Common Stock, shares issued				560,000
Common Stock, price per share | $ / shares				$ 0.048
Debt Instrument, Converted Amount | $				$ 26,880
Debt Conversion #22
Date of Issuance				Mar. 2, 2015
Common Stock, shares issued				1,215,551
Common Stock, price per share | $ / shares				$ 0.046
Debt Instrument, Converted Amount | $				$ 56,402
Debt Conversion #23
Date of Issuance				Mar. 9, 2015
Common Stock, shares issued				475,182
Common Stock, price per share | $ / shares				$ 0.071
Debt Instrument, Converted Amount | $				$ 33,900
Debt Conversion #24
Date of Issuance				Mar. 10, 2015
Common Stock, shares issued				700,000
Common Stock, price per share | $ / shares				$ 0.036
Debt Instrument, Converted Amount | $				$ 25,200
Debt Conversion #25
Date of Issuance				Mar. 20, 2015
Common Stock, shares issued				181,818
Common Stock, price per share | $ / shares				$ 0.006
Debt Instrument, Converted Amount | $				$ 10,000
Debt Conversion #26
Date of Issuance		Apr. 1, 2015		Apr. 1, 2015
Common Stock, shares issued		411,111		411,111
Common Stock, price per share | $ / shares		$ 0.04050		$ 0.04050
Debt Instrument, Converted Amount | $		$ 16,650		$ 16,650
Debt Conversion #27
Date of Issuance		Apr. 6, 2015		Apr. 6, 2015
Common Stock, shares issued		209,644		209,644
Common Stock, price per share | $ / shares		$ 0.04770		$ 0.04770
Debt Instrument, Converted Amount | $		$ 10,000		$ 10,000
Debt Conversion #28
Date of Issuance		Apr. 8, 2015		Apr. 8, 2015
Common Stock, shares issued		453,561		453,561
Common Stock, price per share | $ / shares		$ 0.03375		$ 0.03375
Debt Instrument, Converted Amount | $		$ 15,309		$ 15,309
Debt Conversion #29
Date of Issuance		Apr. 9, 2015		Apr. 9, 2015
Common Stock, shares issued		325,455		325,455
Common Stock, price per share | $ / shares		$ 0.04400		$ 0.04400
Debt Instrument, Converted Amount | $		$ 14,320		$ 14,320
Debt Conversion #30
Date of Issuance		Apr. 14, 2015		Apr. 14, 2015
Common Stock, shares issued		236,967		236,967
Common Stock, price per share | $ / shares		$ 0.04220		$ 0.04220
Debt Instrument, Converted Amount | $		$ 10,000		$ 10,000
Debt Conversion #31
Date of Issuance		Apr. 16, 2015		Apr. 16, 2015
Common Stock, shares issued		53,000		53,000
Common Stock, price per share | $ / shares		$ 0.03619		$ 0.03619
Debt Instrument, Converted Amount | $		$ 1,918		$ 1,918
Debt Conversion #32
Date of Issuance		Apr. 21, 2015		Apr. 21, 2015
Common Stock, shares issued		259,740		259,740
Common Stock, price per share | $ / shares		$ 0.03850		$ 0.03850
Debt Instrument, Converted Amount | $		$ 10,000		$ 10,000
Debt Conversion #33
Date of Issuance		Apr. 29, 2015		Apr. 29, 2015
Common Stock, shares issued		389,610		389,610
Common Stock, price per share | $ / shares		$ 0.03850		$ 0.03850
Debt Instrument, Converted Amount | $		$ 15,000		$ 15,000
Debt Conversion #34
Date of Issuance		May 4, 2015		May 4, 2015
Common Stock, shares issued		131,464		131,464
Common Stock, price per share | $ / shares		$ 0.03866		$ 0.03866
Debt Instrument, Converted Amount | $		$ 5,083		$ 5,083
Debt Conversion #35
Date of Issuance		May 12, 2015		May 12, 2015
Common Stock, shares issued		903,380		903,380
Common Stock, price per share | $ / shares		$ 0.03150		$ 0.03150
Debt Instrument, Converted Amount | $		$ 28,456		$ 28,456
Debt Conversion #36
Date of Issuance		May 20, 2015		May 20, 2015
Common Stock, shares issued		947,645		947,645
Common Stock, price per share | $ / shares		$ 0.02131		$ 0.02131
Debt Instrument, Converted Amount | $		$ 20,199		$ 20,199
Debt Conversion #37
Date of Issuance		May 20, 2015		May 20, 2015
Common Stock, shares issued		783,636		783,636
Common Stock, price per share | $ / shares		$ 0.02200		$ 0.02200
Debt Instrument, Converted Amount | $		$ 17,240		$ 17,240
Debt Conversion #38
Date of Issuance		May 27, 2015		May 27, 2015
Common Stock, shares issued		701,801		701,801
Common Stock, price per share | $ / shares		$ 0.01933		$ 0.01933
Debt Instrument, Converted Amount | $		$ 13,568		$ 13,568
Debt Conversion #39
Date of Issuance		May 29, 2015		May 29, 2015
Common Stock, shares issued		882,353		882,353
Common Stock, price per share | $ / shares		$ 0.01700		$ 0.01700
Debt Instrument, Converted Amount | $		$ 15,000		$ 15,000
Debt Conversion #40
Date of Issuance		Jun. 11, 2015		Jun. 11, 2015
Common Stock, shares issued		942,609		942,609
Common Stock, price per share | $ / shares		$ 0.01050		$ 0.01050
Debt Instrument, Converted Amount | $		$ 9,897		$ 9,897
Debt Conversion #41
Date of Issuance		Jun. 16, 2015		Jun. 16, 2015
Common Stock, shares issued		1,175,000		1,175,000
Common Stock, price per share | $ / shares		$ 0.01200		$ 0.01200
Debt Instrument, Converted Amount | $		$ 14,100		$ 14,100
Debt Conversion #42
Date of Issuance		Jun. 16, 2015		Jun. 16, 2015
Common Stock, shares issued		1,130,417		1,130,417
Common Stock, price per share | $ / shares		$ 0.01200		$ 0.01200
Debt Instrument, Converted Amount | $		$ 13,565		$ 13,565
Debt Conversion #43
Date of Issuance		Apr. 8, 2015		Apr. 8, 2015
Common Stock, shares issued		454,545		454,545
Common Stock, price per share | $ / shares		$ 0.04400		$ 0.04400
Debt Instrument, Converted Amount | $		$ 20,001		$ 20,001
Debt Conversion #44
Date of Issuance		Jun. 22, 2015		Jun. 22, 2015
Common Stock, shares issued		1,235,833		1,235,833
Common Stock, price per share | $ / shares		$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $		$ 7,415		$ 7,415
Debt Conversion #45
Date of Issuance		Jun. 22, 2015		Jun. 22, 2015
Common Stock, shares issued		2,479,924		2,479,924
Common Stock, price per share | $ / shares		$ 0.00580		$ 0.00580
Debt Instrument, Converted Amount | $		$ 14,384		$ 14,384
Debt Conversion #46
Date of Issuance		Jun. 23, 2015		Jun. 23, 2015
Common Stock, shares issued		1,292,000		1,292,000
Common Stock, price per share | $ / shares		$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $		$ 7,752		$ 7,752
Debt Conversion #47
Date of Issuance		Sep. 16, 2015		Sep. 16, 2015
Common Stock, shares issued		1,772,033		1,772,033
Common Stock, price per share | $ / shares		$ 0.00450		$ 0.00450
Debt Instrument, Converted Amount | $		$ 7,974		$ 7,974
Debt Conversion #48
Date of Issuance		Sep. 28, 2015		Sep. 28, 2015
Common Stock, shares issued		1,666,667		1,666,667
Common Stock, price per share | $ / shares		$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $		$ 10,000		$ 10,000
Debt Conversion #49
Date of Issuance		Sep. 29, 2015		Sep. 29, 2015
Common Stock, shares issued		1,770,000		1,770,000
Common Stock, price per share | $ / shares		$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $		$ 10,620		$ 10,620
Debt Conversion #50
Date of Issuance		Oct. 7, 2015		Oct. 7, 2015
Common Stock, shares issued		375,000		375,000
Common Stock, price per share | $ / shares		$ 0.0060		$ 0.0060
Debt Instrument, Converted Amount | $		$ 2,250		$ 2,250
Debt Conversion #51
Date of Issuance		Oct. 7, 2015		Oct. 7, 2015
Common Stock, shares issued		1,400,000		1,400,000
Common Stock, price per share | $ / shares		$ 0.0060		$ 0.0060
Debt Instrument, Converted Amount | $		$ 8,400		$ 8,400
Debt Conversion #52
Date of Issuance		Oct. 19, 2015		Oct. 19, 2015
Common Stock, shares issued		1,620,000		1,620,000
Common Stock, price per share | $ / shares		$ 0.0060		$ 0.0060
Debt Instrument, Converted Amount | $		$ 9,720		$ 9,720
Debt Conversion #53
Date of Issuance		Nov. 2, 2015		Nov. 2, 2015
Common Stock, shares issued		1,966,124		1,966,124
Common Stock, price per share | $ / shares		$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $		$ 4,424		$ 4,424
Debt Conversion #54
Date of Issuance		Nov. 23, 2015		Nov. 23, 2015
Common Stock, shares issued		1,666,667		1,666,667
Common Stock, price per share | $ / shares		$ 0.0060		$ 0.0060
Debt Instrument, Converted Amount | $		$ 10,000		$ 10,000
Debt Conversion #55
Date of Issuance		Nov. 30, 2015		Nov. 30, 2015
Common Stock, shares issued		2,591,323		2,591,323
Common Stock, price per share | $ / shares		$ 0.00650		$ 0.00650
Debt Instrument, Converted Amount | $		$ 16,844		$ 16,844
Debt Conversion #56
Date of Issuance		Dec. 9, 2015		Dec. 9, 2015
Common Stock, shares issued		775,991		775,991
Common Stock, price per share | $ / shares		$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $		$ 1,746		$ 1,746
Debt Conversion #57
Date of Issuance		Dec. 17, 2015		Dec. 17, 2015
Common Stock, shares issued		919,319		919,319
Common Stock, price per share | $ / shares		$ 0.00580		$ 0.00580
Debt Instrument, Converted Amount | $		$ 5,332		$ 5,332
Debt Conversion #58
Date of Issuance		Dec. 28, 2015		Dec. 28, 2015
Common Stock, shares issued		596,200		596,200
Common Stock, price per share | $ / shares		$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $		$ 1,341		$ 1,341
Debt Conversion #59
Date of Issuance		Dec. 28, 2015		Dec. 28, 2015
Common Stock, shares issued		2,950,000		2,950,000
Common Stock, price per share | $ / shares		$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $		$ 17,700		$ 17,700
Debt Conversion #60
Date of Issuance		Dec. 28, 2015		Dec. 28, 2015
Common Stock, shares issued		2,384,167		2,384,167
Common Stock, price per share | $ / shares		$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $		$ 14,305		$ 14,305
Debt Conversion #61
Date of Issuance		Dec. 28, 2015		Dec. 28, 2015
Common Stock, shares issued		2,579,916		2,579,916
Common Stock, price per share | $ / shares		$ 0.00580		$ 0.00580
Debt Instrument, Converted Amount | $		$ 14,963		$ 14,963
Debt Conversion #62
Date of Issuance		Dec. 29, 2015		Dec. 29, 2015
Common Stock, shares issued		1,399,167		1,399,167
Common Stock, price per share | $ / shares		$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $		$ 8,395		$ 8,395
Debt Conversion #63
Date of Issuance		Dec. 29, 2015		Dec. 29, 2015
Common Stock, shares issued		1,278,333		1,278,333
Common Stock, price per share | $ / shares		$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $		$ 7,670		$ 7,670
Debt Conversion #64
Date of Issuance		Dec. 30, 2015		Dec. 30, 2015
Common Stock, shares issued		2,956,248		2,956,248
Common Stock, price per share | $ / shares		$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $		$ 6,651		$ 6,651
2013 Stock Option Plan Amendment
Date of Agreement		Jan. 12, 2015		Jan. 12, 2015
Options granted, number of shares		672,533		672,533
Exercise price | $ / shares		$ 0.17		$ 0.17
Stock-based compensation | $		$ 50,448		$ 50,448
2013 Stock Option Plan Amdt #2
Date of Agreement		Apr. 6, 2015		Apr. 6, 2015
Options granted, number of shares		2,712,535		2,712,535
Exercise price | $ / shares		$ 0.08		$ 0.08
Stock-based compensation | $		$ 9,316		$ 9,316
2013 Stock Option Plan Amdt #3
Date of Agreement		Aug. 4, 2015		Aug. 4, 2015
Options granted, number of shares		3,712,535		3,712,535
Exercise price | $ / shares		$ 0.02		$ 0.02
Stock-based compensation | $		$ 47,463		$ 47,463
Debt Conversion #65
Date of Issuance		Jan. 4, 2016		Jan. 4, 2016
Common Stock, shares issued		3,223,213		3,223,213
Common Stock, price per share | $ / shares		$ 0.006		$ 0.006
Debt Instrument, Converted Amount | $		$ 19,339		$ 19,339
Debt Conversion #66
Date of Issuance		Jan. 5, 2016		Jan. 5, 2016
Common Stock, shares issued		3,603,227		3,603,227
Common Stock, price per share | $ / shares		$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $		$ 8,107		$ 8,107
Debt Conversion #67
Date of Issuance		Jan. 6, 2016		Jan. 6, 2016
Common Stock, shares issued		2,678,333		2,678,333
Common Stock, price per share | $ / shares		$ 0.006		$ 0.006
Debt Instrument, Converted Amount | $		$ 16,070		$ 16,070
Debt Conversion #68
Date of Issuance		Jan. 6, 2016		Jan. 6, 2016
Common Stock, shares issued		2,861,607		2,861,607
Common Stock, price per share | $ / shares		$ 0.0058		$ 0.0058
Debt Instrument, Converted Amount | $		$ 16,597		$ 16,597
Debt Conversion #69
Date of Issuance		Feb. 16, 2016		Feb. 16, 2016
Common Stock, shares issued		4,220,400		4,220,400
Common Stock, price per share | $ / shares		$ 0.00034		$ 0.00034
Debt Instrument, Converted Amount | $		$ 1,424		$ 1,424
Debt Conversion #70
Date of Issuance		Feb. 17, 2016		Feb. 17, 2016
Common Stock, shares issued		8,443,272		8,443,272
Common Stock, price per share | $ / shares		$ 0.00152		$ 0.00152
Debt Instrument, Converted Amount | $		$ 12,800		$ 12,800
Debt Conversion #71
Date of Issuance		Feb. 23, 2016		Feb. 23, 2016
Common Stock, shares issued		4,218,182		4,218,182
Common Stock, price per share | $ / shares		$ 0.0011		$ 0.0011
Debt Instrument, Converted Amount | $		$ 4,640		$ 4,640
Debt Conversion #72
Date of Issuance		Feb. 23, 2016		Feb. 23, 2016
Common Stock, shares issued		4,200,871		4,200,871
Common Stock, price per share | $ / shares		$ 0.00073		$ 0.00073
Debt Instrument, Converted Amount | $		$ 3,086		$ 3,086
Debt Conversion #73
Date of Issuance		Feb. 24, 2016		Feb. 24, 2016
Common Stock, shares issued		4,419,970		4,419,970
Common Stock, price per share | $ / shares		$ 0.00034		$ 0.00034
Debt Instrument, Converted Amount | $		$ 1,492		$ 1,492
Debt Conversion #74
Date of Issuance		Feb. 25, 2016		Feb. 25, 2016
Common Stock, shares issued		2,638,987		2,638,987
Common Stock, price per share | $ / shares		$ 0.00114		$ 0.00114
Debt Instrument, Converted Amount | $		$ 3,000		$ 3,000
Debt Conversion #75
Date of Issuance		Feb. 25, 2016		Feb. 25, 2016
Common Stock, shares issued		4,218,182		4,218,182
Common Stock, price per share | $ / shares		$ 0.0011		$ 0.0011
Debt Instrument, Converted Amount | $		$ 4,640		$ 4,640
Debt Conversion #76
Date of Issuance		Mar. 1, 2016		Mar. 1, 2016
Common Stock, shares issued		5,834,458		5,834,458
Common Stock, price per share | $ / shares		$ 0.00022		$ 0.00022
Debt Instrument, Converted Amount | $		$ 1,313		$ 1,313
Debt Conversion #77
Date of Issuance		Mar. 2, 2016		Mar. 2, 2016
Common Stock, shares issued		5,831,642		5,831,642
Common Stock, price per share | $ / shares		$ 0.00079		$ 0.00079
Debt Instrument, Converted Amount | $		$ 4,600		$ 4,600
Debt Conversion #78
Date of Issuance		Mar. 2, 2016		Mar. 2, 2016
Common Stock, shares issued		2,586,410		2,586,410
Common Stock, price per share | $ / shares		$ 0.00064		$ 0.00064
Debt Instrument, Converted Amount | $		$ 1,650		$ 1,650
Debt Conversion #79
Date of Issuance		Mar. 2, 2016		Mar. 2, 2016
Common Stock, shares issued		11,650,000		11,650,000
Common Stock, price per share | $ / shares		$ 0.0008		$ 0.0008
Debt Instrument, Converted Amount | $		$ 9,332		$ 9,332
Debt Conversion #80
Date of Issuance		Mar. 7, 2016		Mar. 7, 2016
Common Stock, shares issued		6,546,292		6,546,292
Common Stock, price per share | $ / shares		$ 0.00043		$ 0.00043
Debt Instrument, Converted Amount | $		$ 2,799		$ 2,799
Debt Conversion #81
Date of Issuance		Mar. 11, 2016		Mar. 11, 2016
Common Stock, shares issued		4,147,500		4,147,500
Common Stock, price per share | $ / shares		$ 0.00046		$ 0.00046
Debt Instrument, Converted Amount | $		$ 1,924		$ 1,924
Debt Conversion #82
Date of Issuance		Mar. 14, 2016		Mar. 14, 2016
Common Stock, shares issued		7,125,777		7,125,777
Common Stock, price per share | $ / shares		$ 0.00032		$ 0.00032
Debt Instrument, Converted Amount | $		$ 2,245		$ 2,245
Debt Conversion #83
Date of Issuance		Mar. 15, 2016		Mar. 15, 2016
Common Stock, shares issued		7,454,098		7,454,098
Common Stock, price per share | $ / shares		$ 0.00045		$ 0.00045
Debt Instrument, Converted Amount | $		$ 3,329		$ 3,329
Debt Conversion #84
Date of Issuance		Mar. 15, 2016		Mar. 15, 2016
Common Stock, shares issued		11,450,000		11,450,000
Common Stock, price per share | $ / shares		$ 0.00046		$ 0.00046
Debt Instrument, Converted Amount | $		$ 5,210		$ 5,210
Debt Conversion #85
Date of Issuance		Mar. 22, 2016		Mar. 22, 2016
Common Stock, shares issued		8,957,888		8,957,888
Common Stock, price per share | $ / shares		$ 0.00027		$ 0.00027
Debt Instrument, Converted Amount | $		$ 2,419		$ 2,419
Debt Conversion #86
Date of Issuance		Mar. 22, 2016		Mar. 22, 2016
Common Stock, shares issued		7,200,486		7,200,486
Common Stock, price per share | $ / shares		$ 0.00033		$ 0.00033
Debt Instrument, Converted Amount | $		$ 2,367		$ 2,367
Debt Conversion #87
Date of Issuance		Mar. 22, 2016		Mar. 22, 2016
Common Stock, shares issued		11,682,000		11,682,000
Common Stock, price per share | $ / shares		$ 0.00046		$ 0.00046
Debt Instrument, Converted Amount | $		$ 5,315		$ 5,315
Debt Conversion #88
Date of Issuance		Mar. 28, 2016		Mar. 28, 2016
Common Stock, shares issued		8,958,779		8,958,779
Common Stock, price per share | $ / shares		$ 0.00022		$ 0.00022
Debt Instrument, Converted Amount | $		$ 1,986		$ 1,986
Asset Assign Agmt #2
Date of Agreement		Oct. 6, 2014		Oct. 6, 2014
Common Stock, shares issued		2,207,920		2,207,920
Deemed Dividend | $				$ 7,822,235
Asset Assign Agmt
Date of Agreement		Jul. 18, 2015		Jul. 18, 2015
Common Stock, shares issued		827,670		827,670
Series A Preferred Stock, shares issued		6,000,000		6,000,000
Shares Issued, Value | $		$ 123,973		$ 123,973
Sale Agmt
Shares agreed to cancel		2,625,210		2,625,210
Shares returned to treasury		5,002,554		5,002,554
Date of Agreement		Jul. 19, 2013		Jul. 19, 2013
Consultant
Shares issued for services				25,000
Shares issued for services, value | $				$ 300,000
Exercise Date				May 7, 2014
Stock Deposits
Common Stock, shares issued				14,690
Shares Issued, Value | $				$ 147,050
Exercise Date				Jun. 16, 2014
Legal Services
Shares issued for services				10,000
Shares issued for services, value | $				$ 60,000
Exercise Date				Jul. 1, 2014
Loss on issuance of stock | $				$ (30,000)
CEO
Date of Agreement				Oct. 6, 2014
Shares issued for services				80,000
Attorney
Date of Agreement				Oct. 6, 2014
Shares issued for services				40,000
Attorney & CEO
Shares issued for services, value | $				$ 429,600
Vendor
Date of Agreement				Nov. 19, 2014
Shares issued for services				5,000
Shares issued for services, value | $				$ 6,450
Investment Agmt
Date of Agreement				Aug. 13, 2014
Shares issued for services				799,619
Shares issued for services, value | $				$ 220,000
Sale of Stock #1
Issuance of common stock for cash, shares		100,381		100,381
Issuance of common stock for cash, amount | $		$ 5,405		$ 5,405
Date of Issuance		Apr. 22, 2015		Apr. 22, 2015
Sale of Stock #2
Issuance of common stock for cash, shares		1,542,455		1,542,455
Issuance of common stock for cash, amount | $		$ 10,797		$ 10,797
Date of Issuance		Jun. 25, 2015		Jun. 25, 2015
Sale of Stock #3
Issuance of common stock for cash, shares		1,619,423		1,619,423
Issuance of common stock for cash, amount | $		$ 11,336		$ 11,336
Date of Issuance		Jul. 7, 2015		Jul. 7, 2015
Sale of Stock #4
Issuance of common stock for cash, shares		1,439,282		1,439,282
Issuance of common stock for cash, amount | $		$ 10,075		$ 10,075
Date of Issuance		Jul. 15, 2015		Jul. 15, 2015
Sale of Stock #5
Issuance of common stock for cash, shares		1,648,840		1,648,840
Issuance of common stock for cash, amount | $		$ 11,542		$ 11,542
Date of Issuance		Oct. 27, 2015		Oct. 27, 2015

Equity Transactions (Details 51

Equity Transactions (Details Narrative) 9M	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2016USD ($)shares	Mar. 31, 2016$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014shares	Sep. 30, 2013	Mar. 31, 2013	May 23, 2016shares	Sep. 06, 2013$ / sharesshares	Sep. 05, 2013$ / sharesshares	Jul. 18, 2013shares
Common Stock, Shares Authorized		4,000,000,000	4,000,000,000		4,000,000,000	4,000,000,000				4,000,000,000	375,030,000	900,000
Common Stock, Par Value | $ / shares		$ 0.001	$ 0.001		$ 0.001	$ .001					$ 0.001	$ 0.001
Preferred Stock, Shares Authorized		10,000,000	10,000,000		10,000,000	10,000,000
Preferred Stock, Par Value | $ / shares		$ .001	$ 0.001		$ .001	$ .001
Series A Preferred Stock, Designated													6,000,000
Common Stock, Issued		216,364,262	1,307,401,310		216,364,262	15,410,840
Preferred Stock, Issued		6,000,000	6,000,000		6,000,000	6,000,000
Common Stock, shares issued						14,690
Stock split ratio			0.01		4.167			4.167	4.1671
Options granted, number of shares		3,900,003			3,900,003	197,500	475,033
Shares issued for services							1,182,141
Shares issued for services, value | $					$ 49,155	$ 796,050
Debt Instrument, Converted Amount | $			$ 109,144	$ 454,077	602,374	499,686
Stock-based compensation | $				$ 198,128	$ 240,999	$ 866,128
Debt Conversion #26
Date of Issuance			Apr. 1, 2015		Apr. 1, 2015
Common Stock, shares issued			411,111		411,111
Common Stock, price per share | $ / shares			$ 0.04050		$ 0.04050
Debt Instrument, Converted Amount | $			$ 16,650		$ 16,650
Debt Conversion #27
Date of Issuance			Apr. 6, 2015		Apr. 6, 2015
Common Stock, shares issued			209,644		209,644
Common Stock, price per share | $ / shares			$ 0.04770		$ 0.04770
Debt Instrument, Converted Amount | $			$ 10,000		$ 10,000
Debt Conversion #28
Date of Issuance			Apr. 8, 2015		Apr. 8, 2015
Common Stock, shares issued			453,561		453,561
Common Stock, price per share | $ / shares			$ 0.03375		$ 0.03375
Debt Instrument, Converted Amount | $			$ 15,309		$ 15,309
Debt Conversion #29
Date of Issuance			Apr. 9, 2015		Apr. 9, 2015
Common Stock, shares issued			325,455		325,455
Common Stock, price per share | $ / shares			$ 0.04400		$ 0.04400
Debt Instrument, Converted Amount | $			$ 14,320		$ 14,320
Debt Conversion #30
Date of Issuance			Apr. 14, 2015		Apr. 14, 2015
Common Stock, shares issued			236,967		236,967
Common Stock, price per share | $ / shares			$ 0.04220		$ 0.04220
Debt Instrument, Converted Amount | $			$ 10,000		$ 10,000
Debt Conversion #31
Date of Issuance			Apr. 16, 2015		Apr. 16, 2015
Common Stock, shares issued			53,000		53,000
Common Stock, price per share | $ / shares			$ 0.03619		$ 0.03619
Debt Instrument, Converted Amount | $			$ 1,918		$ 1,918
Debt Conversion #32
Date of Issuance			Apr. 21, 2015		Apr. 21, 2015
Common Stock, shares issued			259,740		259,740
Common Stock, price per share | $ / shares			$ 0.03850		$ 0.03850
Debt Instrument, Converted Amount | $			$ 10,000		$ 10,000
Debt Conversion #33
Date of Issuance			Apr. 29, 2015		Apr. 29, 2015
Common Stock, shares issued			389,610		389,610
Common Stock, price per share | $ / shares			$ 0.03850		$ 0.03850
Debt Instrument, Converted Amount | $			$ 15,000		$ 15,000
Debt Conversion #34
Date of Issuance			May 4, 2015		May 4, 2015
Common Stock, shares issued			131,464		131,464
Common Stock, price per share | $ / shares			$ 0.03866		$ 0.03866
Debt Instrument, Converted Amount | $			$ 5,083		$ 5,083
Debt Conversion #35
Date of Issuance			May 12, 2015		May 12, 2015
Common Stock, shares issued			903,380		903,380
Common Stock, price per share | $ / shares			$ 0.03150		$ 0.03150
Debt Instrument, Converted Amount | $			$ 28,456		$ 28,456
Debt Conversion #36
Date of Issuance			May 20, 2015		May 20, 2015
Common Stock, shares issued			947,645		947,645
Common Stock, price per share | $ / shares			$ 0.02131		$ 0.02131
Debt Instrument, Converted Amount | $			$ 20,199		$ 20,199
Debt Conversion #37
Date of Issuance			May 20, 2015		May 20, 2015
Common Stock, shares issued			783,636		783,636
Common Stock, price per share | $ / shares			$ 0.02200		$ 0.02200
Debt Instrument, Converted Amount | $			$ 17,240		$ 17,240
Debt Conversion #38
Date of Issuance			May 27, 2015		May 27, 2015
Common Stock, shares issued			701,801		701,801
Common Stock, price per share | $ / shares			$ 0.01933		$ 0.01933
Debt Instrument, Converted Amount | $			$ 13,568		$ 13,568
Debt Conversion #39
Date of Issuance			May 29, 2015		May 29, 2015
Common Stock, shares issued			882,353		882,353
Common Stock, price per share | $ / shares			$ 0.01700		$ 0.01700
Debt Instrument, Converted Amount | $			$ 15,000		$ 15,000
Debt Conversion #40
Date of Issuance			Jun. 11, 2015		Jun. 11, 2015
Common Stock, shares issued			942,609		942,609
Common Stock, price per share | $ / shares			$ 0.01050		$ 0.01050
Debt Instrument, Converted Amount | $			$ 9,897		$ 9,897
Debt Conversion #41
Date of Issuance			Jun. 16, 2015		Jun. 16, 2015
Common Stock, shares issued			1,175,000		1,175,000
Common Stock, price per share | $ / shares			$ 0.01200		$ 0.01200
Debt Instrument, Converted Amount | $			$ 14,100		$ 14,100
Debt Conversion #42
Date of Issuance			Jun. 16, 2015		Jun. 16, 2015
Common Stock, shares issued			1,130,417		1,130,417
Common Stock, price per share | $ / shares			$ 0.01200		$ 0.01200
Debt Instrument, Converted Amount | $			$ 13,565		$ 13,565
Debt Conversion #43
Date of Issuance			Apr. 8, 2015		Apr. 8, 2015
Common Stock, shares issued			454,545		454,545
Common Stock, price per share | $ / shares			$ 0.04400		$ 0.04400
Debt Instrument, Converted Amount | $			$ 20,001		$ 20,001
Debt Conversion #44
Date of Issuance			Jun. 22, 2015		Jun. 22, 2015
Common Stock, shares issued			1,235,833		1,235,833
Common Stock, price per share | $ / shares			$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,415		$ 7,415
Debt Conversion #45
Date of Issuance			Jun. 22, 2015		Jun. 22, 2015
Common Stock, shares issued			2,479,924		2,479,924
Common Stock, price per share | $ / shares			$ 0.00580		$ 0.00580
Debt Instrument, Converted Amount | $			$ 14,384		$ 14,384
Debt Conversion #46
Date of Issuance			Jun. 23, 2015		Jun. 23, 2015
Common Stock, shares issued			1,292,000		1,292,000
Common Stock, price per share | $ / shares			$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,752		$ 7,752
Debt Conversion #47
Date of Issuance			Sep. 16, 2015		Sep. 16, 2015
Common Stock, shares issued			1,772,033		1,772,033
Common Stock, price per share | $ / shares			$ 0.00450		$ 0.00450
Debt Instrument, Converted Amount | $			$ 7,974		$ 7,974
Debt Conversion #48
Date of Issuance			Sep. 28, 2015		Sep. 28, 2015
Common Stock, shares issued			1,666,667		1,666,667
Common Stock, price per share | $ / shares			$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $			$ 10,000		$ 10,000
Debt Conversion #49
Date of Issuance			Sep. 29, 2015		Sep. 29, 2015
Common Stock, shares issued			1,770,000		1,770,000
Common Stock, price per share | $ / shares			$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $			$ 10,620		$ 10,620
Debt Conversion #50
Date of Issuance			Oct. 7, 2015		Oct. 7, 2015
Common Stock, shares issued			375,000		375,000
Common Stock, price per share | $ / shares			$ 0.0060		$ 0.0060
Debt Instrument, Converted Amount | $			$ 2,250		$ 2,250
Debt Conversion #51
Date of Issuance			Oct. 7, 2015		Oct. 7, 2015
Common Stock, shares issued			1,400,000		1,400,000
Common Stock, price per share | $ / shares			$ 0.0060		$ 0.0060
Debt Instrument, Converted Amount | $			$ 8,400		$ 8,400
Debt Conversion #52
Date of Issuance			Oct. 19, 2015		Oct. 19, 2015
Common Stock, shares issued			1,620,000		1,620,000
Common Stock, price per share | $ / shares			$ 0.0060		$ 0.0060
Debt Instrument, Converted Amount | $			$ 9,720		$ 9,720
Debt Conversion #53
Date of Issuance			Nov. 2, 2015		Nov. 2, 2015
Common Stock, shares issued			1,966,124		1,966,124
Common Stock, price per share | $ / shares			$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $			$ 4,424		$ 4,424
Debt Conversion #54
Date of Issuance			Nov. 23, 2015		Nov. 23, 2015
Common Stock, shares issued			1,666,667		1,666,667
Common Stock, price per share | $ / shares			$ 0.0060		$ 0.0060
Debt Instrument, Converted Amount | $			$ 10,000		$ 10,000
Debt Conversion #55
Date of Issuance			Nov. 30, 2015		Nov. 30, 2015
Common Stock, shares issued			2,591,323		2,591,323
Common Stock, price per share | $ / shares			$ 0.00650		$ 0.00650
Debt Instrument, Converted Amount | $			$ 16,844		$ 16,844
Debt Conversion #56
Date of Issuance			Dec. 9, 2015		Dec. 9, 2015
Common Stock, shares issued			775,991		775,991
Common Stock, price per share | $ / shares			$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $			$ 1,746		$ 1,746
Debt Conversion #57
Date of Issuance			Dec. 17, 2015		Dec. 17, 2015
Common Stock, shares issued			919,319		919,319
Common Stock, price per share | $ / shares			$ 0.00580		$ 0.00580
Debt Instrument, Converted Amount | $			$ 5,332		$ 5,332
Debt Conversion #58
Date of Issuance			Dec. 28, 2015		Dec. 28, 2015
Common Stock, shares issued			596,200		596,200
Common Stock, price per share | $ / shares			$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $			$ 1,341		$ 1,341
Debt Conversion #59
Date of Issuance			Dec. 28, 2015		Dec. 28, 2015
Common Stock, shares issued			2,950,000		2,950,000
Common Stock, price per share | $ / shares			$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $			$ 17,700		$ 17,700
Debt Conversion #60
Date of Issuance			Dec. 28, 2015		Dec. 28, 2015
Common Stock, shares issued			2,384,167		2,384,167
Common Stock, price per share | $ / shares			$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $			$ 14,305		$ 14,305
Debt Conversion #61
Date of Issuance			Dec. 28, 2015		Dec. 28, 2015
Common Stock, shares issued			2,579,916		2,579,916
Common Stock, price per share | $ / shares			$ 0.00580		$ 0.00580
Debt Instrument, Converted Amount | $			$ 14,963		$ 14,963
Debt Conversion #62
Date of Issuance			Dec. 29, 2015		Dec. 29, 2015
Common Stock, shares issued			1,399,167		1,399,167
Common Stock, price per share | $ / shares			$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $			$ 8,395		$ 8,395
Debt Conversion #63
Date of Issuance			Dec. 29, 2015		Dec. 29, 2015
Common Stock, shares issued			1,278,333		1,278,333
Common Stock, price per share | $ / shares			$ 0.00600		$ 0.00600
Debt Instrument, Converted Amount | $			$ 7,670		$ 7,670
Debt Conversion #64
Date of Issuance			Dec. 30, 2015		Dec. 30, 2015
Common Stock, shares issued			2,956,248		2,956,248
Common Stock, price per share | $ / shares			$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $			$ 6,651		$ 6,651
2013 Stock Option Plan Amendment
Date of Agreement			Jan. 12, 2015		Jan. 12, 2015
Options granted, number of shares			672,533		672,533
Exercise price | $ / shares			$ 0.17		$ 0.17
Stock-based compensation | $			$ 50,448		$ 50,448
2013 Stock Option Plan Amdt #2
Date of Agreement			Apr. 6, 2015		Apr. 6, 2015
Options granted, number of shares			2,712,535		2,712,535
Exercise price | $ / shares			$ 0.08		$ 0.08
Stock-based compensation | $			$ 9,316		$ 9,316
2013 Stock Option Plan Amdt #3
Date of Agreement			Aug. 4, 2015		Aug. 4, 2015
Options granted, number of shares			3,712,535		3,712,535
Exercise price | $ / shares			$ 0.02		$ 0.02
Stock-based compensation | $			$ 47,463		$ 47,463
Debt Conversion #65
Date of Issuance			Jan. 4, 2016		Jan. 4, 2016
Common Stock, shares issued			3,223,213		3,223,213
Common Stock, price per share | $ / shares			$ 0.006		$ 0.006
Debt Instrument, Converted Amount | $			$ 19,339		$ 19,339
Debt Conversion #66
Date of Issuance			Jan. 5, 2016		Jan. 5, 2016
Common Stock, shares issued			3,603,227		3,603,227
Common Stock, price per share | $ / shares			$ 0.00225		$ 0.00225
Debt Instrument, Converted Amount | $			$ 8,107		$ 8,107
Debt Conversion #67
Date of Issuance			Jan. 6, 2016		Jan. 6, 2016
Common Stock, shares issued			2,678,333		2,678,333
Common Stock, price per share | $ / shares			$ 0.006		$ 0.006
Debt Instrument, Converted Amount | $			$ 16,070		$ 16,070
Debt Conversion #68
Date of Issuance			Jan. 6, 2016		Jan. 6, 2016
Common Stock, shares issued			2,861,607		2,861,607
Common Stock, price per share | $ / shares			$ 0.0058		$ 0.0058
Debt Instrument, Converted Amount | $			$ 16,597		$ 16,597
Debt Conversion #69
Date of Issuance			Feb. 16, 2016		Feb. 16, 2016
Common Stock, shares issued			4,220,400		4,220,400
Common Stock, price per share | $ / shares			$ 0.00034		$ 0.00034
Debt Instrument, Converted Amount | $			$ 1,424		$ 1,424
Debt Conversion #70
Date of Issuance			Feb. 17, 2016		Feb. 17, 2016
Common Stock, shares issued			8,443,272		8,443,272
Common Stock, price per share | $ / shares			$ 0.00152		$ 0.00152
Debt Instrument, Converted Amount | $			$ 12,800		$ 12,800
Debt Conversion #71
Date of Issuance			Feb. 23, 2016		Feb. 23, 2016
Common Stock, shares issued			4,218,182		4,218,182
Common Stock, price per share | $ / shares			$ 0.0011		$ 0.0011
Debt Instrument, Converted Amount | $			$ 4,640		$ 4,640
Debt Conversion #72
Date of Issuance			Feb. 23, 2016		Feb. 23, 2016
Common Stock, shares issued			4,200,871		4,200,871
Common Stock, price per share | $ / shares			$ 0.00073		$ 0.00073
Debt Instrument, Converted Amount | $			$ 3,086		$ 3,086
Debt Conversion #73
Date of Issuance			Feb. 24, 2016		Feb. 24, 2016
Common Stock, shares issued			4,419,970		4,419,970
Common Stock, price per share | $ / shares			$ 0.00034		$ 0.00034
Debt Instrument, Converted Amount | $			$ 1,492		$ 1,492
Debt Conversion #74
Date of Issuance			Feb. 25, 2016		Feb. 25, 2016
Common Stock, shares issued			2,638,987		2,638,987
Common Stock, price per share | $ / shares			$ 0.00114		$ 0.00114
Debt Instrument, Converted Amount | $			$ 3,000		$ 3,000
Debt Conversion #75
Date of Issuance			Feb. 25, 2016		Feb. 25, 2016
Common Stock, shares issued			4,218,182		4,218,182
Common Stock, price per share | $ / shares			$ 0.0011		$ 0.0011
Debt Instrument, Converted Amount | $			$ 4,640		$ 4,640
Debt Conversion #76
Date of Issuance			Mar. 1, 2016		Mar. 1, 2016
Common Stock, shares issued			5,834,458		5,834,458
Common Stock, price per share | $ / shares			$ 0.00022		$ 0.00022
Debt Instrument, Converted Amount | $			$ 1,313		$ 1,313
Debt Conversion #77
Date of Issuance			Mar. 2, 2016		Mar. 2, 2016
Common Stock, shares issued			5,831,642		5,831,642
Common Stock, price per share | $ / shares			$ 0.00079		$ 0.00079
Debt Instrument, Converted Amount | $			$ 4,600		$ 4,600
Debt Conversion #78
Date of Issuance			Mar. 2, 2016		Mar. 2, 2016
Common Stock, shares issued			2,586,410		2,586,410
Common Stock, price per share | $ / shares			$ 0.00064		$ 0.00064
Debt Instrument, Converted Amount | $			$ 1,650		$ 1,650
Debt Conversion #79
Date of Issuance			Mar. 2, 2016		Mar. 2, 2016
Common Stock, shares issued			11,650,000		11,650,000
Common Stock, price per share | $ / shares			$ 0.0008		$ 0.0008
Debt Instrument, Converted Amount | $			$ 9,332		$ 9,332
Debt Conversion #80
Date of Issuance			Mar. 7, 2016		Mar. 7, 2016
Common Stock, shares issued			6,546,292		6,546,292
Common Stock, price per share | $ / shares			$ 0.00043		$ 0.00043
Debt Instrument, Converted Amount | $			$ 2,799		$ 2,799
Debt Conversion #81
Date of Issuance			Mar. 11, 2016		Mar. 11, 2016
Common Stock, shares issued			4,147,500		4,147,500
Common Stock, price per share | $ / shares			$ 0.00046		$ 0.00046
Debt Instrument, Converted Amount | $			$ 1,924		$ 1,924
Debt Conversion #82
Date of Issuance			Mar. 14, 2016		Mar. 14, 2016
Common Stock, shares issued			7,125,777		7,125,777
Common Stock, price per share | $ / shares			$ 0.00032		$ 0.00032
Debt Instrument, Converted Amount | $			$ 2,245		$ 2,245
Debt Conversion #83
Date of Issuance			Mar. 15, 2016		Mar. 15, 2016
Common Stock, shares issued			7,454,098		7,454,098
Common Stock, price per share | $ / shares			$ 0.00045		$ 0.00045
Debt Instrument, Converted Amount | $			$ 3,329		$ 3,329
Debt Conversion #84
Date of Issuance			Mar. 15, 2016		Mar. 15, 2016
Common Stock, shares issued			11,450,000		11,450,000
Common Stock, price per share | $ / shares			$ 0.00046		$ 0.00046
Debt Instrument, Converted Amount | $			$ 5,210		$ 5,210
Debt Conversion #85
Date of Issuance			Mar. 22, 2016		Mar. 22, 2016
Common Stock, shares issued			8,957,888		8,957,888
Common Stock, price per share | $ / shares			$ 0.00027		$ 0.00027
Debt Instrument, Converted Amount | $			$ 2,419		$ 2,419
Debt Conversion #86
Date of Issuance			Mar. 22, 2016		Mar. 22, 2016
Common Stock, shares issued			7,200,486		7,200,486
Common Stock, price per share | $ / shares			$ 0.00033		$ 0.00033
Debt Instrument, Converted Amount | $			$ 2,367		$ 2,367
Debt Conversion #87
Date of Issuance			Mar. 22, 2016		Mar. 22, 2016
Common Stock, shares issued			11,682,000		11,682,000
Common Stock, price per share | $ / shares			$ 0.00046		$ 0.00046
Debt Instrument, Converted Amount | $			$ 5,315		$ 5,315
Debt Conversion #88
Date of Issuance			Mar. 28, 2016		Mar. 28, 2016
Common Stock, shares issued			8,958,779		8,958,779
Common Stock, price per share | $ / shares			$ 0.00022		$ 0.00022
Debt Instrument, Converted Amount | $			$ 1,986		$ 1,986
Debt Conversion #89
Date of Issuance	Apr. 1, 2016		Apr. 1, 2016
Common Stock, shares issued	9,766,311		9,766,311
Common Stock, price per share | $ / shares			$ 0.000225
Debt Instrument, Converted Amount | $	$ 2,158		$ 2,197
Debt Conversion #90
Date of Issuance			Apr. 4, 2016
Common Stock, shares issued			17,250,000
Common Stock, price per share | $ / shares			$ 0.000281
Debt Instrument, Converted Amount | $			$ 4,847
Debt Conversion #91
Date of Issuance			Apr. 7, 2016
Common Stock, shares issued			9,722,222
Common Stock, price per share | $ / shares			$ 0.000180
Debt Instrument, Converted Amount | $			$ 1,750
Debt Conversion #92
Date of Issuance			Apr. 14, 2016
Common Stock, shares issued			19,250,000
Common Stock, price per share | $ / shares			$ 0.000216
Debt Instrument, Converted Amount | $			$ 4,158
Debt Conversion #93
Date of Issuance			Apr. 15, 2016
Common Stock, shares issued			9,766,222
Common Stock, price per share | $ / shares			$ 0.000135
Debt Instrument, Converted Amount | $			$ 1,318
Debt Conversion #94
Date of Issuance			Apr. 26, 2016
Common Stock, shares issued			12,629,776
Common Stock, price per share | $ / shares			$ 0.000135
Debt Instrument, Converted Amount | $			$ 1,705
Debt Conversion #95
Date of Issuance			May 4, 2016
Common Stock, shares issued			9,718,025
Common Stock, price per share | $ / shares			$ 0.000213
Debt Instrument, Converted Amount | $			$ 2,067
Debt Conversion #96
Date of Issuance			May 31, 2016
Common Stock, shares issued			4,600,055
Common Stock, price per share | $ / shares			$ 0.000180
Debt Instrument, Converted Amount | $			$ 828
Debt Conversion #97
Date of Issuance			Jun. 2, 2016
Common Stock, shares issued			30,000,000
Common Stock, price per share | $ / shares			$ 0.000304
Debt Instrument, Converted Amount | $			$ 9,120
Debt Conversion #98
Date of Issuance			Jun. 2, 2016
Common Stock, shares issued			29,340,333
Common Stock, price per share | $ / shares			$ 0.000150
Debt Instrument, Converted Amount | $			$ 4,401
Debt Conversion #99
Date of Issuance			Jun. 14, 2016
Common Stock, shares issued			29,235,900
Common Stock, price per share | $ / shares			$ 0.000200
Debt Instrument, Converted Amount | $			$ 5,847
Debt Conversion #100
Date of Issuance			Jun. 17, 2016
Common Stock, shares issued			28,456,150
Common Stock, price per share | $ / shares			$ 0.000200
Debt Instrument, Converted Amount | $			$ 5,691
Debt Conversion #101
Date of Issuance			Jun. 29, 2017
Common Stock, shares issued			21,270,355
Common Stock, price per share | $ / shares			$ 0.000309
Debt Instrument, Converted Amount | $			$ 6,580
Debt Conversion #102
Date of Issuance			Aug. 23, 2016
Common Stock, shares issued			22,129,741
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,567
Debt Conversion #103
Date of Issuance			Aug. 29, 2016
Common Stock, shares issued			22,156,120
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,570
Debt Conversion #104
Date of Issuance			Sep. 6, 2016
Common Stock, shares issued			21,952,672
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,547
Debt Conversion #105
Date of Issuance			Sep. 20, 2016
Common Stock, shares issued			25,267,355
Common Stock, price per share | $ / shares			$ 0.000097
Debt Instrument, Converted Amount | $			$ 2,443
Debt Conversion #106
Date of Issuance			Sep. 26, 2016
Common Stock, shares issued			25,393,447
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,946
Debt Conversion #107
Date of Issuance			Sep. 28, 2016
Common Stock, shares issued			25,403,448
Common Stock, price per share | $ / shares			$ 0.000116
Debt Instrument, Converted Amount | $			$ 2,947
Debt Conversion #108
Date of Issuance			Sep. 30, 2016
Common Stock, shares issued			51,066,724
Common Stock, price per share | $ / shares			$ 0.000077
Debt Instrument, Converted Amount | $			$ 3,949
Debt Conversion #109
Date of Issuance			Oct. 7, 2016
Common Stock, shares issued			58,291,551
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 3,381
Debt Conversion #110
Date of Issuance			Oct. 14, 2016
Common Stock, shares issued			58,275,689
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 3,380
Debt Conversion #111
Date of Issuance			Oct. 21, 2016
Common Stock, shares issued			58,355,689
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 3,385
Debt Conversion #112
Date of Issuance			Oct. 26, 2016
Common Stock, shares issued			58,316,551
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 3,382
Debt Conversion #113
Date of Issuance			Oct. 31, 2016
Common Stock, shares issued			86,837,068
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 5,037
Debt Conversion #114
Date of Issuance			Nov. 7, 2016
Common Stock, shares issued			86,472,931
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 5,015
Debt Conversion #115
Date of Issuance			Nov. 22, 2016
Common Stock, shares issued			95,060,172
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 5,513
Debt Conversion #116
Date of Issuance			Nov. 29, 2016
Common Stock, shares issued			95,092,931
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 5,515
Debt Conversion #117
Date of Issuance			Dec. 6, 2016
Common Stock, shares issued			69,959,310
Common Stock, price per share | $ / shares			$ 0.000058
Debt Instrument, Converted Amount | $			$ 4,058
Asset Assign Agmt
Date of Agreement			Jul. 18, 2015		Jul. 18, 2015
Common Stock, shares issued			827,670		827,670
Series A Preferred Stock, shares issued			6,000,000		6,000,000
Shares Issued, Value | $			$ 123,973		$ 123,973
Sale Agmt
Shares agreed to cancel			2,625,210		2,625,210
Shares returned to treasury			5,002,554		5,002,554
Date of Agreement			Jul. 19, 2013		Jul. 19, 2013
Warrant #1
Exercise Date			Oct. 29, 2013		Oct. 29, 2013
Warrants | $			$ 2,500		$ 2,500
Stock price on grant date | $ / shares			$ 30		$ 30
Exercise price | $ / shares			$ 50		$ 50
Expected life			1 year		1 year
Warrant #2
Exercise Date			Dec. 11, 2013		Dec. 11, 2013
Warrants | $			$ 2,500		$ 2,500
Stock price on grant date | $ / shares			$ 30		$ 2
Exercise price | $ / shares			$ 50		$ 50
Expected life			1 year		1 year
Warrant #3
Exercise Date			Jun. 9, 2015		Mar. 10, 2014
Warrants | $			$ 900,000		$ 833
Stock price on grant date | $ / shares					$ 2
Exercise price | $ / shares			$ 0.02		$ 50
Expected life			5 years		1 year
Warrant #4
Exercise Date			Dec. 15, 2016		Apr. 4, 2014
Warrants | $			$ 4,000,000		$ 833
Stock price on grant date | $ / shares					$ 19.90
Exercise price | $ / shares			$ 0.01		$ 50
Expected life			5 years		1 year
Sale of Stock #1
Issuance of common stock for cash, shares			100,381		100,381
Issuance of common stock for cash, amount | $			$ 5,405		$ 5,405
Date of Issuance			Apr. 22, 2015		Apr. 22, 2015
Sale of Stock #2
Issuance of common stock for cash, shares			1,542,455		1,542,455
Issuance of common stock for cash, amount | $			$ 10,797		$ 10,797
Date of Issuance			Jun. 25, 2015		Jun. 25, 2015
Sale of Stock #3
Issuance of common stock for cash, shares			1,619,423		1,619,423
Issuance of common stock for cash, amount | $			$ 11,336		$ 11,336
Date of Issuance			Jul. 7, 2015		Jul. 7, 2015
Sale of Stock #4
Issuance of common stock for cash, shares			1,439,282		1,439,282
Issuance of common stock for cash, amount | $			$ 10,075		$ 10,075
Date of Issuance			Jul. 15, 2015		Jul. 15, 2015
Sale of Stock #5
Issuance of common stock for cash, shares			1,648,840		1,648,840
Issuance of common stock for cash, amount | $			$ 11,542		$ 11,542
Date of Issuance			Oct. 27, 2015		Oct. 27, 2015

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2016	Mar. 31, 2016
Monthly Rent	$ 2,800	$ 2,800
Contract
Date of Agreement	Jul. 8, 2016
Contract Duration	27 months
Contract Committment Value	$ 193,255

Income Taxes - Schedule of Fede

Income Taxes - Schedule of Federal Income Tax (Details) - USD ($)	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Federal income tax benefit attributable to:
Current operations	$ 601,276	$ 1,405,416
Less: valuation allowance	(601,276)	(1,405,416)
Net provision for Federal income taxes	$ 0	$ 0

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Asset (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Deferred tax asset attributable to:
Net operating loss carryover	$ 3,129,170	$ 2,454,951
Less: valuation allowance	(3,129,170)	(2,454,951)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Mar. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Net Operating Loss Carry-Forwards	$ 9,203,440
Operating Loss Carry-Forwards Expiration Date	Jan. 1, 2033
Effective Tax Rate	34.00%

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	May 23, 2016	Sep. 06, 2013	Sep. 05, 2013
Common Stock, Shares Authorized		4,000,000,000		4,000,000,000	4,000,000,000	4,000,000,000	375,030,000	900,000
Debt Instrument, Converted Amount		$ 109,144	$ 454,077	$ 602,374	$ 499,686
Debt Instrument, Interest Accrued, Converted Amount		$ 9,584
Common Stock, shares issued					14,690
Debt Conversion #89
Date of Issuance	Apr. 1, 2016	Apr. 1, 2016
Debt Instrument, Converted Amount	$ 2,158	$ 2,197
Debt Instrument, Interest Accrued, Converted Amount	$ 39
Common Stock, shares issued	9,766,311	9,766,311
Common Stock, price per share		$ 0.000225
Convertible Prom Note #30
Date of Agreement	Jun. 9, 2016
Convertible Note	$ 84,250
Interest Rate	8.00%
Due Date	Jun. 8, 2017
Convertible Prom Note #31
Date of Agreement	Jun. 9, 2016
Convertible Note	$ 84,250
Interest Rate	8.00%
Due Date	Jun. 8, 2017
Convertible Prom Note #32
Date of Agreement	Jun. 25, 2016
Convertible Note	$ 56,000
Interest Rate	8.00%
Due Date	Jun. 23, 2017
Convertible Prom Note #33
Date of Agreement	Jun. 25, 2016
Convertible Note	$ 56,000
Interest Rate	8.00%
Due Date	Jun. 23, 2017
Convertible Prom Note #34
Date of Agreement	May 25, 2016
Convertible Note	$ 30,000
Interest Rate	8.00%
Due Date	May 25, 2017
Debt Conversion #90
Date of Issuance	Apr. 4, 2016
Debt Instrument, Converted Amount	$ 4,847
Common Stock, shares issued	17,250,000
Debt Conversion #91
Date of Issuance	Apr. 7, 2016
Debt Instrument, Converted Amount	$ 1,699
Debt Instrument, Interest Accrued, Converted Amount	$ 51
Common Stock, shares issued	9,722,222
Debt Conversion #92
Date of Issuance	Apr. 14, 2016
Debt Instrument, Converted Amount	$ 4,158
Common Stock, shares issued	19,250,000
Debt Conversion #93
Date of Issuance	Apr. 15, 2016
Debt Instrument, Converted Amount	$ 1,259
Debt Instrument, Interest Accrued, Converted Amount	$ 59
Common Stock, shares issued	9,766,222
Debt Conversion #94
Date of Issuance	May 31, 2016
Debt Instrument, Converted Amount	$ 828
Common Stock, shares issued	4,600,055
Debt Conversion #95
Date of Issuance	Jun. 3, 2016
Debt Instrument, Converted Amount	$ 4,401
Common Stock, shares issued	29,340,333
Debt Conversion #96
Date of Issuance	Jun. 7, 2016
Debt Instrument, Converted Amount	$ 9,120
Common Stock, shares issued	30,000,000
Debt Conversion #97
Date of Issuance	Jun. 14, 2016
Debt Instrument, Converted Amount	$ 5,847
Common Stock, shares issued	29,235,900
Debt Conversion #98
Date of Issuance	Jun. 17, 2016
Debt Instrument, Converted Amount	$ 5,691
Common Stock, shares issued	28,456,150

Subsequent Event (Details Nar57

Subsequent Event (Details Narrative) 9M - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Debt Instrument, Converted Amount		$ 109,144	$ 454,077	$ 602,374	$ 499,686
Debt Instrument, Interest Accrued, Converted Amount		$ 9,584
Common Stock, shares issued					14,690
Debt Conversion #118
Date of Issuance	Jan. 10, 2017
Debt Instrument, Converted Amount	$ 6,000
Debt Instrument, Interest Accrued, Converted Amount	$ 301
Common Stock, shares issued	126,023,000
Convertible Prom Note #38
Date of Agreement	Jan. 5, 2017
Convertible Note	$ 335,000
Interest Rate	10.00%
Due Date	Oct. 5, 2017

Uncategorized Items - rcha-2016

Label	Element	Value
Stock options granted for services, shares	RCHA_StockOptionsGrantedForServicesShares	23,825
Stock split - 416.7 to 1	RCHA_StockSplit
Stock and warrants issued for cash, amount	RCHA_StockAndWarrantsIssuedForCash1	175,000
Stock issued for intangible assets, amount	RCHA_StockIssuedForIntangibleAssets1	123,973
Shares cancellation, amount	RCHA_SharesCancellation1
Forgiveness of shareholder debt	RCHA_ForgivenessOfShareholderDebt	28,818
Stock options granted for services	us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims	$ 663,307
Common Stock
Stock issued for intangible assets, shares	RCHA_StockIssuedForIntangibleAssets	827,670
Stock and warrants issued for cash, shares	RCHA_StockAndWarrantsIssuedForCash	5,833
Stock and warrants issued for cash, amount	RCHA_StockAndWarrantsIssuedForCash1	$ 6
Stock issued for intangible assets, amount	RCHA_StockIssuedForIntangibleAssets1	828
Shares cancellation, amount	RCHA_SharesCancellation1	$ (7,628)
Shares cancellation, shares	RCHA_SharesCancellation	(7,627,764)
Preferred Stock
Stock issued for intangible assets, shares	RCHA_StockIssuedForIntangibleAssets	6,000,000
Stock issued for intangible assets, amount	RCHA_StockIssuedForIntangibleAssets1	$ 6,000
Additional Paid-In Capital
Stock issued for services, shares	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices	1,182,141
Stock options granted for services, shares	RCHA_StockOptionsGrantedForServicesShares	23,825
Stock split - 416.7 to 1	RCHA_StockSplit	$ 214,537
Stock and warrants issued for cash, amount	RCHA_StockAndWarrantsIssuedForCash1	174,994
Stock issued for intangible assets, amount	RCHA_StockIssuedForIntangibleAssets1	117,145
Shares cancellation, amount	RCHA_SharesCancellation1	7,628
Forgiveness of shareholder debt	RCHA_ForgivenessOfShareholderDebt	28,818
Stock options granted for services	us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims	$ 663,307
Accumulated Deficit
Stock issued for services, shares	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Stock options granted for services, shares	RCHA_StockOptionsGrantedForServicesShares
Stock split - 416.7 to 1	RCHA_StockSplit	$ (214,537)
Stock and warrants issued for cash, amount	RCHA_StockAndWarrantsIssuedForCash1
Stock issued for intangible assets, amount	RCHA_StockIssuedForIntangibleAssets1
Shares cancellation, amount	RCHA_SharesCancellation1
Forgiveness of shareholder debt	RCHA_ForgivenessOfShareholderDebt
NET LOSS	us-gaap_NetIncomeLoss	(3,004,937)
Stock options granted for services	us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims